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Small nucleolar RNAs (snoRNAs) are a class of small non-coding RNAs that act as 
guide RNAs for post-transcriptional chemical modifications of ribosomal and 
spliceosome RNAs. Recent independent reports have indicated that these small 
non-coding RNAs are involved in the control of cell fate and their dysfunction or 
dysregulation of their expression might be associated with oncogenesis. SNORD44 
is a C/D box small nucleolar RNA that has been reported to show decreased 
expression levels in breast cancer and head and neck squamous cell carcinoma 
tissues. The SNORD44 host gene is the long non-coding RNA growth arrest specific 
transcript 5 (GAS5), which has been strongly implicated in various types of cancers.  
Expression of SNORD44 has been reported to be decreased in breast cancer cells 
along with leukemic T-cells. However, the function of SNORD44 in the regulation of 
leukemic cell fate is still unknown. In this study, the effects of SNORD44 
overexpression have been investigated in two leukemic T-cell lines, Jurkat and 
CEM-C7. Overexpression of SNORD44 caused a reduction in the number of viable 
and total cell count and an increase in basal apoptosis. Mutations in SNORD44 
abolished the growth inhibitory and proapoptotic effects of SNORD44, suggesting 
that the structure of SNORD44 is important to perform its effects. Treating the cells 
with the pan-caspase inhibitor Z-VAD-FMK also inhibited SNORD44 growth 
inhibitory effects, implicating caspases in SNORD44 mechanisms of action. Overall 
the data showed that SNORD44 has tumour suppressing effects on leukemic T-
cells. From these findings we postulate that control of survival and apoptosis by 
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1.1 Cancer and its hallmarks 
Cancer is a disease in which abnormal cells of the body divide uncontrollably. 
Cancerous cells acquire biological capabilities to be able to evade the body’s 
defences and survive in a tissue micro-environment. There are ten principle 
mechanisms in which cancer cells employ to be able to survive. Hanahan and 
Weinberg (2000) first described six of these hallmarks, the first of these being the 
ability of cancerous cells to sustain proliferative signalling. Normal tissues control 
the release of mitogenic growth signals that progress the cells through the cell cycle, 
but cancerous cells deregulate these signals which enable them to continuously 
progress through the cell cycle and growth cycle from a dormant phase. Mitogenic 
growth signals are usually produced by one cell type but cancer cells acquire the 
ability to produce these mitogenic growth factors themselves to have a continuous 
supply. This method of producing growth factors signals themselves will result in 
autocrine proliferative stimulation. Platelet-derived growth factor (PDGF) is a growth 
factor that is important in blood vessel formation. Glioblastomas are excellent at 
producing this growth factor to allow for an increased blood supply to the tissue 
(Farooqi and Siddik, 2015). 
A second hallmark of cancer is the ability of cells to evade growth suppressors. 
Tumour suppressor genes are already present in cells and have the capability to 
negatively regulate cell proliferation. In tumour cells, these suppressor genes are 
typically downregulated which consequently results in an evasion of senescence 
and apoptosis. The TP53 gene receives information from the cells on stress and 
abnormalities within the genome. When there is damage present in the genome or 
the levels of nutrients required for cell growth are too low, the TP53 gene can inhibit 
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cell cycle progression until the damage or levels of nutrients are fixed by releasing 
the gene product p53. In extreme conditions, p53 can trigger apoptosis to kill cells 
that are irreparable (Hanahan and Weinberg, 2011). Over half of all tumours are 
found to have a mutation or deletion in the TP53 transcription factor gene which 
means that the proteins produced by this gene cannot be produced and therefore 
cannot stop cell cycle progression if cell damage is detected (Gutschner and 
Diederichs, 2012).  
Another hallmark is replicative immortality, the ability to divide indefinitely. Normal 
cells can only replicate a set number of times due to chromosome shortening, 
resulting in cell death. On the other hand, cancerous cells express an enzyme called 
telomerase which has a primary function of adding telomeric repeats to the end of 
telomeres, allowing the cells to carry on replicating. Telomerase is almost non-
existent in mature cells but is found in high quantities in cancerous cells. This 
enables cancerous cells to evade the inevitable senescence seen when normal cells 
reach the end of their replicative potential (Hanahan and Weinberg, 2011).  
The fourth hallmark of cancer cells is the ability to invade other parts of the body 
and metastasize. Cancer cells must undergo biological changes to be able to invade 
other tissues and eventually into the blood system. These biological changes 
include how they attach to the extracellular matrix and other cells. The process of 
cancerous cells being able to move around the body is called the invasion-
metastasis cascade. Local invasion of normal cells is the first process, followed by 
invasion into the blood stream. From the blood stream these cells can travel around 
the body and invade any tissue, forming a secondary tumour (Talmadge and Fidler, 
2010). Integrins are an example of important player in the invasion-metastasis 
cascade when cancerous cells are formed from epithelial cells. Integrins mediate 
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cell adhesion to important components of the extracellular matrix which allows the 
cancer cells to invade other tissues (Talmadge and Fidler, 2010). During this 
process cancerous cells must not be detected by the body’s own defence system.  
Inducing angiogenesis is the fifth hallmark of cancer cells. As the tumour grows, the 
requirement for oxygen and nutrients is increased therefore the cells must find a 
delivery system for these increased requirements. Cancerous cells can form new 
blood vessels to deliver these nutrients straight to the tumour. New blood vessels 
can be formed by inducing pro-angiogenic factors or blocking antiangiogenic 
signals. One of the most well-known angiogenic factors is vascular endothelial 
growth factor-A (VEGF-A) gene. This gene encodes ligands that are used during 
embryonic development as they have an important role in producing new blood 
vessels. Cancer cells can trigger VEGF-A expression which will in turn allows for 
blood vessel production (Ferrara, 2010). This hallmark is one of the first to be 
triggered when a tumour is growing. 
The sixth hallmark is the ability of cancer cells to evade cell death, therefore 
rendering them immortal. TP53 loss or mutation can make cells more resistant to 
apoptosis as it can arrest the cell cycle or induce apoptosis when damage is 
detected within the genome. This mutation/loss is present in 50% of cancers. An 
increased expression of factors that help cell survival can also help cells evade 
apoptosis. An example of one of these apoptotic inhibitors is Bcl-2. Bcl-2 binds to 
Bax and Bak, pro-apoptotic trigger proteins, to inhibit them. When these proteins 
are inhibited, cytochrome C cannot be released and therefore the caspase cascade 




In 2011, Hanahan introduced four new hallmarks of cancer, bringing the total up to 
ten. Figure 1 below shows the most up to date number of hallmarks. 
 
The seventh hallmark proposed is genome instability and mutation. This hallmark 
relies on the basis that some genotypes have a survival advantage over others and 
allow the original six hallmarks to be more successful. Cancer cells can increase the 
rates of mutation within the genome. This ability is performed by increasing the cells 
sensitivity to mutagenic agents, e.g., carcinogens, or by compromising the detection 
systems of damaged cells (Hanahan and Weinberg, 2011). 
The eighth hallmark is inflammation inducing tumour formation. Tumours often have 
many cells from the innate and adaptive immune systems within them. Inflammation 
Figure 1: The ten proposed hallmarks of cancer, including the therapeutic targets for each 
(Hanahan and Weinberg, 2011) The text in coloured outlines shows the possible methods to 
target each hallmark. Genome instability and mutation, tumour-promoting inflammation, 
deregulating cellular energetics and avoiding immune destruction are the 4 new proposed 
hallmarks bringing the total up to 10. 
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provides growth factors, proangiogenic factors and extra-cellular matrix modifying 
enzymes such as matrix metalloproteinases to the tumour microenvironment. 
Similarly, to the seventh hallmark, providing these biological molecules to the 
microenvironment allows the six original hallmarks to be more successful (Hanahan 
and Weinberg, 2011). Inflammatory cells release reactive oxygen species which are 
mutagenic (Grivennikov et al., 2010). This means that any healthy cells nearby may 
become cancerous and help to grow the tumour. 
The ninth hallmark is the ability of cancerous cells to evade immune destruction. 
The immune system is constantly detecting abnormal cells but sometimes these 
cells can evade detection and are able to grow out of control. Tumours can evade 
the immune system in several ways, one of them being damaging cytotoxic T cells 
functionality via the creation and secretion of immune suppressive cytokines. Any 
cell, healthy or not, can produce these cytokines if they are present in the tumour 
microenvironment (Landskron et al., 2014). Cytotoxic T cells are crucial in killing 
cancerous cells along with any cell that has been infected or damaged. 
The final hallmark is the deregulation of normal metabolism pathways. Warburg 
(1930) first described the way in which cancer cells can re-programme the 
metabolism of glucose to purely perform glycolysis, a state which is called ‘aerobic 
glycolysis’. The normal glucose metabolism of oxidation of pyruvate, the citric acid 
cycle and the electron transport chain are halted. Glucose transporters, such as 
GLUT-1, are upregulated in cancer cells to compensate for the lower efficiency of 
ATP production caused by a change to glycolysis as a method of producing glucose. 
An upregulation of glucose transporters leads to more glucose being transported to 
the cytoplasm (Hanahan and Weinberg, 2011). 
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1.2 Role of non-coding RNAs in cancer  
1.2.1 Non-coding RNAs 
The ENCODE project used high-throughput sequencing of transcripts within the 
genome of eukaryotes to reveal that while approximately 90% of genomic DNA is 
transcribed, only 1-2% of the transcribed genomic DNA encodes for proteins (the 
ENCODE Project Consortium et al., 2007). Non-coding RNAs (ncRNAs) are RNA 
molecules that do not translate into a protein and surprisingly compose 88-89% of 
all transcribed genomic DNA. The genome of mammalian cells is transcribed to 
produce sense, antisense, intergenic, intronic and bidirectional ncRNAs (Carninci, 
et al, 2005) which are categorised depending on their distance from protein coding 
genes. An example of this categorisation is ncRNAs located between two genes 
being named intergenic ncRNAs. 
Historically, proteins were considered as the only molecules that could perform 
biological functions; however, this is now known to be false. Jacob and Monod 
(1961) were the first to conclude that ncRNAs regulate genes, however, at the time 
it was still widely believed that ncRNAs only performed basic cell functions that were 
already confirmed, such as transfer ribonucleic acid (tRNA) and ribosomal 
ribonucleic acid (rRNA) being involved in mRNA translation (Mattick and Makunin, 
2006). Brannan et al. (1990) set out to discover new protein coding genes by 
screening a cDNA library of foetal liver but in fact discovered novel ncRNAs which 
were clearly different to the already established classic ncRNAs such as rRNAs and 
tRNAs.  
There have been various controversies surrounding the function of ncRNAs, 
Rajendra et al. (2001) proved that ncRNAs have a role in the developmental process 
not only in mammalian cells but in other organisms such as Drosophila 
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melanogaster. Interestingly, Liu et al. (2013) confirmed that there is a strong 
correlation between the complexity of an organism and the proportion of non-coding 
RNA genes present in the genome. This finding firmly supports the idea that 
ncRNAs must have functional roles within the genome. The hypothesis that these 
ncRNA loci are ‘junk’ is therefore severely outdated and these transcripts should be 
investigated further. The technology to analyse and identify these transcripts has 
improved dramatically in the past decade and consequently new ncRNAs have been 
discovered. Many studies have already been performed and provided substantial 
links between ncRNAs and human diseases. For example, BACE1 is an enzyme 
that has an important role in the formation of Aβ plaques in nerve cells. Inhibition of 
BACE1 may prevent Aβ plaque formation. Faghihi et al. (2008) reported that the 
antisense BACE1 (BACE1-AS) transcript is upregulated 6-fold in patients with 
Alzheimer’s disease compared to healthy patients and the elevated levels of 
BACE1-AS contributes to the disease progression. BACE1 protein production is 
tightly regulated by BACE1-AS, therefore any alterations in levels of BACE1-AS 
could influence the production of BACE1. In this case, the alteration in BACE1-AS 
influences the production of amyloid-beta (Aβ) which can cause the assembly of Aβ 
plaques, a key indicator of Alzheimer’s disease.   
ncRNAs are split into two groups, long non-coding RNA (lncRNAs) and small non-
coding RNAs (sncRNAs). These two groups are differentiated by the length of 
nucleotides, 200 nucleotides or less being sncRNA and any transcripts with more 
than 200 nucleotides is classed as lncRNA (Peschansky and Wahlestedt, 2014). 
1.2.2 Role of long non-coding RNAs 
lncRNAs are classified into six subtypes, antisense, intergenic, overlapping, intronic, 
bidirectional and processed. RNA is classified into these groups depending on the 
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direction and position of transcription when compared against other genes 
(Peschansky and Wahlestedt, 2014). Many of these RNA molecules have important 
functions in regulating gene expression including gene activation and inhibition. An 
insight into the variety of functions lncRNAs perform can be seen in Figure 2. 
 
lncRNAs can either positively or negatively affect the expression of genes. 
Transcription of ncRNAs can negatively affect the ability of genes nearby to be 
expressed. If transcription of a ncRNA along the promoter region of another RNA 
would inhibit transcription factor binding, there would be no expression of the RNA. 
Another function of lncRNAs is to act as a precursor to other smaller non-coding 
RNAs. miRNAs can be produced by the cleavage of lncRNAs by drosha and dicer. 
lncRNAs can also affect the location and function of the proteins they bind to. 
NRON (noncoding repressor of NFAT) is a lncRNA that is a key regulator in the 
Figure 2: An overview of the functions of lncRNA. The blue boxes show the introns and exons 
and the yellow box shows the initial lncRNA gene. (1) Transcription of lncRNA can either 
positively (green arrow) or negatively (red arrow) (2) effect the expression of a nearby gene. (3) 
Antisense of sense RNA can block the recognition of exons to result in alternative splicing or (4) 
Dicer cleavage to produce siRNA. Dicer is an enzyme that cleaves double-stranded RNA and 
pre-microRNA into smaller fragments. Binding of ncRNA to specific proteins can result in protein 
activity being modulated (5). It can also play a structural/organisational role that forms a complex 
(6) or it can change where the protein is in the cell (7). LncRNA can be further processed to 
produce sncRNA (8) (Wilusz et al., 2009). 
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movement of NFAT around the cell. NRON binds to cytoplasmic machinery to inhibit 
the accumulation of NFAT (Wilusz et al., 2009). 
Long intergenic non-coding RNAs (lincRNA) are a subset of lncRNAs that are 
classified based on their location between protein coding genes. There is an 
estimated 3,000 lincRNA genes present in the human genome but only 1% of these 
have been fully investigated (Khalil et al., 2009). Identifying lincRNA molecules that 
are present in cancer cells in either significantly lower or higher levels than normal 
cells could determine whether they function in oncogenesis. Ching et al., (2016) 
performed this analysis identifying lincRNAs relating to tumour diagnosis, subtyping 
cancers and prognosis of the disease, and identified thousands of differentially 
expressed lincRNA genes in only 12 cancer types. From this study, they were able 
to identify a group of six lincRNAs that could be potentially used as pan-cancer 
diagnostic biomarkers. These lincRNAs are PCAN-1, PCAN-2, PCAN-3, PCAN-4, 
PCAN-5 and PCAN-6. More recently, a link between knockdown of lincRNA-p21 
and the increased radio sensitivity of hypoxic tumour cells was identified which could 
enhance radiotherapy treatment of cancer (Shen et al., 2017).  
One of the earliest lincRNAs discovered is X-inactive specific transcript (Xist) that is 
15-17kb long and the gene is located on the X chromosome. This RNA is transcribed 
from the XIST gene (Brown et al., 1991) and is important in X inactivation. X 
inactivation ensures that the transcript levels are equal between males and females. 
Xist has already been shown to be upregulated in several types of cancer which 
suggests a potential for its use in biomarker diagnostics (Hu et al., 2017). Due to 
Xist possessing a huge role in development and growth, it is natural to investigate 
its potential as a target to inhibit cancer cell growth. Yildirim et al. (2013) have proved 
that Xist deletion in the stem cells of glioblastoma patients decreased cell 
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proliferation and promoted apoptosis (Yildirim et al., 2013).  The study also 
confirmed that Xist and miR-152 have a reciprocal suppressive effect which 
indicates there is some relationship between the two ncRNAs. Expanding on this 
point, the binding active site of Xist is functional for miR-152 therefore some 
silencing effects by the miR-152 could be occurring via the RNA-induced silencing 
complex (RISC). The RISC is a ribonucleoprotein complex with a single strand RNA 
incorporated. This single stand acts as a template for the complex to eventually 
cleave target mRNA via argonaute (Pratt and MacRae, 2009). The RISC acts in a 
post-transcriptional fashion. Metastasis associated lung adenocarcinoma transcript 
1 (MALAT-1) is an extensively studied lincRNA regarding its involvement in cancer. 
Ji et al. (2003) first discovered MALAT-1 at high levels in non-small cell lung cancer. 
MALAT-1 is 8000 nt long and expressed from chromosome 11q13. MALAT-1 is 
conserved in a variety of species which suggests its importance for cell function (Ma 
et al., 2015). In breast cancer, this lincRNA is upregulated significantly (Guffanti et 
al., 2009) and has the potential to be used as a diagnostic biomarker. The levels of 
MALAT-1 varies from cancer to cancer therefore a specific threshold of what is 
considered an upregulation must be established before any research is performed. 
Following on from this point, the potential for MALAT-1 to be a diagnostic biomarker 
has been researched. Wang et al. (2016) used the GEO database to determine if 
MALAT-1 can be used as a biomarker. A total of 19 datasets were identified from 
the GEO database with a total of 2142 samples. The data collected showed that 
MALAT-1 can be used as a biomarker in a variety of cancers as an indicator of 
good/bad prognosis. Li et al. (2017) concur with the previous conclusion and 
concludes that MALAT-1 can be used a biomarker for bladder cancer. To determine 
the functions of MALAT-1, the relationship between MALAT-1 levels and overall 
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Figure 3 shows that the levels of MALAT-1 correlate to cancer progression, including 
the migration of cancer to the lymph nodes. Han et al. (2013) agreed with these 
results finding that levels of MALAT-1 are elevated in invasive bladder cancer 
compared to non-invasive. Detecting the levels of MALAT-1 in patients could 
determine the intensity of treatment needed based on the overall survival rate and 
in turn can determine prognosis.  
Luan et al. (2016) analysed that MALAT-1 acts as a competing RNA to sponge miR-
22 to promote malignant melanoma growth and metastasis. This research was 
crucial in understanding how lncRNAs interact with other RNA molecules such as 
miRNAs. Subsequent studies have been executed exploring possible interactions 
between MALAT-1 and miRNAs with the intention to understand how MALAT-1 is 
involved in cancer. Zuo et al. (2017) determined that MALAT-1 induces proliferation 
Figure 3: Relationship between MALAT-1 levels and the overall survival of patients with bladder 
cancer. Kaplan-Meier plot to show the relationship between expression of MALAT-1 and the 
overall survival of patients in months (Li et al., 2017) 
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and invasion of cancer cells by targeting miR-129-5p in triple-negative breast 
cancer. Both studies hint at using MALAT-1 as a target for a novel cancer therapy. 
1.2.3 Role of Small non-coding RNAs in cancer  
Since the discovery of sncRNAs (Lee et al, 1993; Hamilton and Baulcombe, 1999), 
the understanding of how gene expression is controlled has been altered 
considerably. High throughput RNA/DNA sequencing has been a reliable method to 
identify a variety of these small non-coding RNAs (Ryvkin et al., 2014). This group 
of ncRNAs can be differentiated further into subgroups depending on their 
properties and functions including how they are produced. These subgroups are 
microRNAs (miRNAs), small interfering RNA (siRNAs), piwi-interacting 
RNAs (piRNAs), small nucleolar RNAs (snoRNAs), small nuclear 
RNA (snRNAs), extracellular RNA (exRNAs), and small cajal body-specific RNA 
(scaRNAs). snoRNAs are a class of small non-coding RNA that has a primary 
function of inducing chemical modifications of other RNAs, including transfer and 
ribosomal RNA. Modification can include methylation and pseudouridylation.  
Small non-coding RNAs have important roles in cancer development and 
progression. miRNAs have already been discovered to have tumour suppression 
and oncogenic properties (Zhou et al., 2017). They are also involved in drug 
resistance of cancer and can be used as biomarkers to detect the presence of 
cancer (Ogata-Kawata et al., 2014).  
miRNAs originate from pri-miRNA that is cleaved by Drosha to form pre-miRNA in 
the nucleus. The pre-miRNA is then cleaved by DICER to form smaller fragments 
of RNA called miRNA. miRNA genes are transcribed by RNA polymerase II. They 
are involved in RNA silencing along with post-transcriptional regulation of gene 
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expression. miRNAs use complementary base sequencing to silence target mRNAs 
(Wahid et al., 2010). The first link between miRNAs and cancer was established by 
Calin et al. (2004) whilst examining chronic lymphocytic leukaemia (CLL). It was 
found that an area on chromosome 13q14 that is deleted when a patient has CLL, 
in fact is made up of two genes that code for miRNAs. This finding lead to the same 
research group mapping 186 miRNAs and comparing their location to the regions 
involved in genetic mutations. It was concluded that 52.5% of the miRNAs mapped 
were in cancer-associated regions. This discovery sparked a revolution of research 
into the roles of miRNAs in cancer progression and diagnostics.  
miRNAs have shown great promise in being possible diagnostic tools for cancer. 
Ogata-Kawata et al. (2014) identified that seven miRNAs, miR-1229, miR-1246, 
miR-150, miR-21, let-7a, miR-223 and miR-23a, had higher levels in the serum 
samples of colon cancer patients at every stage of the disease. To add to this, the 
same study identified that colon cancer cell lines expressed these miRNAs at higher 
levels than normal colon cell lines. Mishra et al. (2015) investigated further into the 
possibilities of miRNAs as biomarkers by expression profiling peripheral blood 
mononuclear cells (PBMCs) of breast cancer patients. From the expression profile 
created, 40 miRNAs were validated and analysed in PBMCs, blood plasma and 
breast tissue samples. Alongside these factors, the expression of miRNAs was also 
analysed in PBMCs from patients in early and advanced stage breast cancer and 
patients that had triple negative and positive diagnosis. It was concluded that in early 
stage breast cancer miR-195-5p and miR-495 levels are downregulated therefore a 
combination of these miRNAs could potentially be used as biomarkers for early 
stage breast cancer. Todeschini et al. (2017) concur with Ogata-Kawata et al. (2014) 
and Mishra et al. (2015) on the view that miRNA can be used as future biomarkers. 
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Todeschini et al. (2017) reported that miR-1246 can be used as a diagnostic marker 
in high-grade ovarian carcinoma. miR-1246, miR-595 and miR-2278 were found to 
be at elevated levels in the sera of HGSOC patients compared to healthy 
controls. Using Receiver Operating Characteristic curves, it was found that miR-
1246 was the most suitable to use as a diagnostic marker for this type of cancer due 
to its accuracy of 84%.  
Several lines of evidence have also implicated miRNAs in drug resistance. For 
example, Chen et al. (2016) confirmed a relationship between many miRNAs and 
drug resistance in breast cancer tissues in vivo. This study indicates that 9 miRNAs 
can be used to optimise chemotherapy drug dispensing so analyse which drugs will 
be most effective in specific patients. The breast cancer Formalin-Fixed Paraffin-
Embedded (FFPE) tissue from a patient can be extracted and be used in vivo to 
profile the expression of miRNAs that play a role in chemoresistance. Kovalchuk et 
al. (2008) has established that miR-451 regulates the expression of multidrug 
resistance protein 1 (MDR1) gene. MDR1 is found in the cell membrane and pumps 
foreign substances out of the cell. Additionally, transfection of miR-451 into MCF-7 
cells resulted in an increased sensitivity to the chemotherapy drug doxorubicin. 
Normalising levels of miR-451 could therefore lead to drug resistance being 
reduced. 
siRNAs are double stranded small RNAs of 20-25 nt in length, that take part in 
regulating gene expression. They regulate gene expression by degrading target 
mRNAs after transcription so that they cannot be translated. These ncRNAs are 
produced by the dicer enzyme from double stranded RNA and small hairpin RNAs. 
Following on from miRNA being involved in chemotherapy drug resistance, there 
have been a plethora of studies performed with siRNAs to overcome the same 
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problem due to its role in interfering with gene expression. Azimi et al. (2017) 
explored the use of siRNAs to overcome drug resistance to doxorubicin with the aim 
of supressing the expression of p53R2. Saad et al. (2008) concluded that siRNA 
targeted to BCL2, MRP1 and MDR1 mRNA induces apoptosis in HepG2 cells. Using 
doxorubicin in combination with these targeted siRNA requires a smaller dosage to 
kill cancer cells. Polo-like kinase-1 (PLK1) has already been identified as a target 
for tumour suppression as it is essential for spindle formation in mitosis (Spänkuch-
Schmitt et al., 2002). This study also suggested an opportunity to investigate the 
anti-proliferative effects of siRNA in relation to PLK1.  
Li et al. (2016) generated a multi-target siRNA pool as a possible therapeutic 
technique in hepatocellular carcinoma (HCC) targeting Neuroepithelial cell 
transforming 1 (NET-1), cortactin gene (EMS1) and vascular endothelial growth 
factor (VEGF).  NET-1 is a gene involved in cancer cell proliferation, EMS1 is 
involved in cancer cell motility and VEGF promotes angiogenesis. Inhibiting the 
expression of these genes would potentially inhibit the cancer cell survival. Indeed, 
the study showed that the proliferation and migration of cancer cells were inhibited 
when the mutli-target siRNAs pool was transfected into HCC cells. Apoptosis was 
also induced in the cells transfected with the siRNA pool. The study provided 
evidence that there is a therapeutic potential for such approach.  
snoRNAs are another subclass of small non-coding RNAs in which the current study 
will be focused on. The function of many of these RNAs in cancer are yet to be fully 
understood. The rest of this section will be focused on snoRNAs. 
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1.3 Small nucleolar RNAs (snoRNAs) 
snoRNAs are a subtype of sncRNAs that are known to have an important role in the 
post-transcriptional modification of ribosomal RNAs and small nuclear RNAs 
(snRNAs). Such modifications are essential for the biogenesis of ribosomes.  In 
addition to their role in ribosomal RNA biogenesis, emerging evidence is implicating 
snoRNAs in several cellular functions including alternative RNA splicing, regulation 
of chromatin structure, metabolism, and oncogenesis (Warner et al., 2018).  
Typically, snoRNAs are 60-300 nt long, single stranded and can be mainly classified 
into two types based on the presence of highly conserved sequences. These include 
C/D box snoRNAs (SNORDs) and H/ACA box snoRNAs (SNORAs) (Balakin et al., 
1996). C/D box snoRNAs are associated with 2'-O-methylation whilst H/ACA box 
snoRNAs are associated with pseudouridylation. Figure 6 below depicts the 
differences between these two types of snoRNAs. 
 
Most snoRNAs are found already encoded within the transcript of other genes, also 
known as ‘host genes’ but also can be transcribed from RNA polymerase II or III 
Figure 6: Diagram to show the two types of snoRNAs. (A) a C/D box snoRNA. (B) a H/ACA box 
snoRNA. The C/D box snoRNAs contain the motifs of C (RUGAUGA) and D (CUGA) whilst the 




units. snoRNA can associate themselves with ribonucleoproteins (RNP) to form a 
new molecule called snoRNPs which in turn have their own individual function to 
regulate rRNA. The C/D box snoRNPs regulate specific 2′-O-methylation of ribose 
(Kiss-laszlo et al., 1996) while the H/ACA snoRNPs catalyse isomerization of uridine 
(Ganot et al., 1997). A third category of snoRNAs have been discovered, named 
small Cajal body-specific RNAs (scaRNAs). These scaRNAs are found in Cajal 
bodies and have an important role in post-transcriptional modification including 
methylation and pseudouridylation, of spliceosomal small nuclear RNAs U1, U2, U4, 
U5, and U12 (Scott and Ono, 2011). 
1.3.1 Role of snoRNAs in cancer  
snoRNAs are of interest due to their proven involvement in oncogenic diseases such 
as cancer. The first link between snoRNAs and carcinogenesis was made by Chang 
et al., (2002) where h5sn2 was found to be highly expressed in a normal brain while 
its expression level in patients with meningioma was greatly decreased. This 
correlation discovery sparked a burst of research on snoRNAs in recent years.  
An example of snoRNAs involvement in cancer is the effects that altered SNORA42 
levels have on non-small cell lung cancer (NSCLC) progression and tumour growth. 
Mei et al. (2012) reported that the knockdown of SNORA42 inhibited H460 and 
H1944 NSCLC cell colony formation and, when using nude mice animal models, the 
same inhibition of tumour colony formation was observed. Opposing this, the 
overexpression of SNORA42 activates the growth of NSCLC cancer cells according 
to the same study. A strong correlation was shown between expression of 




Dong et al. (2008; 2009) identified a novel C/D box snoRNA, SNORD50A that is 
clinically significant to breast and prostate cancers. SNORD50A (U50) is located 
within chromosome 6q4.31, a locus known to harbour a tumour suppressor gene. 
U50 snoRNA levels were found to be down-regulated in breast and prostate 
cancers. Overexpression of SNORD50A in prostate cancer cells inhibits colony 
formation. Interestingly, a homozygous deletion of 2 base pair in SNORD50A was 
found to be significantly associated with prostate cancer. Overexpression of the 
SNORD50A mutant form abolished the inhibitory effects on colony formation 
observed with overexpression with SNORD50A wild type (Dong et al., 2009). U50 
could therefore be acting as tumour suppressor and a target for a possible therapy 
as it is proven by these studies to play a role in breast and prostate cancer 
development. Yi (2018) performed a study on SNORA42 in relation to its role as an 
oncogene in prostate cancer. This study also looked at the effect of overexpressing 
and knocking down SNORA42 on the cell cycle. Overall, overexpressing SNORA42 
promotes the cell cycle progression. It was also shown that SNORA42 
overexpression decreases basal apoptosis whilst siRNA induced silencing of 
SNORA42 increases basal apoptosis, providing evidence that SNORA42 could act 
as an oncogene. 
The number of snoRNAs investigated thoroughly is low and therefore a gap in 
scientific knowledge is present. Analysing the role of these snoRNAs in cancer may 
lead to novel targets for cancer therapy being established. Gong et al., (2017) 
profiled approximately 10,000 samples of cancer patients covering 31 cancer types 
for the snoRNAs that are involved to further understand the relationship between 
snoRNA and tumorigenesis. 46 snoRNAs were found to be clinically relevant. Figure 
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7 below shows the number of snoRNAs found to be involved in specific cancer 
types. 
 
Figure 7: Graphs to show the spread of snoRNAs found in 31 different cancer types and from 
10,000 samples. (a) A pie chart of the number of samples taken from each cancer type. (b) 
The types of snoRNAs against the number of detectable snoRNAs. (c) The expression of 
snoRNAs against the two types of snoRNAs and scaRNAs. (d) The snoRNAs total expression 
of 14 types of cancer against normal samples (Gong et al., 2017). 
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Figure 7b shows that more than 300 snoRNAs are involved in all 31 cancer types. 
This suggests that snoRNAs may have role in tumorigenesis and could be a 
possible target for therapy. The altered levels of snoRNAs between normal cells and 
cancer cells shown in Figure 7d is a second indication of snoRNAs involvement in 
cancer. An example of one clinically relevant snoRNA identified by this paper was 
C/D box SNORD78, a snoRNA localised in the intronic region of growth arrest 
specific 5 gene (GAS5). SNORD78 has already been identified to be overexpressed 
in NSCLC and prostate cancer, and in this study has proven to have clinical 
significance in 14 cancer types in total, including Cholangiocarcinoma. 
SnoRNAs are small molecules that are relatively stable in serum which stimulated 
research into their potential as disease biomarkers. It is of extreme importance that 
non-small-cell lung cancer (NSCLC) is diagnosed early as it is one of the leading 
causes of cancer related deaths. Liao et al., (2010) performed analysis on patient 
samples that have been diagnosed with NSCLC and found that six snoRNAs are 
significantly associated with NSCLC. These include SNORD33, SNORD66, 
SNORD73B, SNORD76, SNORD78 and SNORA42. The levels of three of these 
snoRNAs, SNORD33, SNORD66 and SNORD76, were found to be significantly 
increased when compared to patients with chronic obstructive pulmonary disease 
(COPD), a disease that shows similar symptoms to NSCLC. This data therefore 
suggests that these three snoRNAs can be used as biomarkers of NSCLC. Yoshida 
et al. (2017) investigated the potential of SNORA21 as a biomarker in human 
colorectal cancer, the second leading cause of death in cancer patients. The study 
used a wide variety of bioinformatics analysis and datasets from 489 colorectal 
cancer tissue samples. Results showed that SNORA21 is significantly upregulated 
in colorectal cancer and its increased levels correlated with metastasis and poor 
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prognosis, highlighting its potential as biomarker for the disease. Xenograft models 
are important as in vitro and in vivo models can react differently when the same 
experiment is performed. In this study, colorectal adenocarcinoma SW48 cells that 
had been treated with CRISPR-SNORA21/Control constructs were injected into 
mice to monitor tumour growth. After 42 days, the tumour growth of the cells with 
the control construct was significantly larger than the CRISPR-SNORA21 construct 
cells. This data indicates that knockdown of SNORA21 reduces tumour growth in 
vivo and confirmed that SNORA21 must be important for tumour growth and could 
be used a biomarker for the disease (Yoshida et al., 2017).    
Many snoRNA are found transcribed from the intronic regions of their ‘host genes’ 
which can be protein coding or non-protein coding. The first host gene discovered 
was the ribosomal protein S1 gene from Xenopus laevis in which several forms of 
U15 snoRNAs are encoded (Pellizzoni et al., 1994). UHG is another host gene that 
encodes the snoRNA U22. This host gene is a lncRNA and does not encode a 
protein product. UHG also encodes seven C/D box antisense snoRNAs, named U25 
to U31 (Frey et al., 1997).  Another lncRNA which acts as snoRNA host gene is 
GAS5. GAS5 plays an important role in controlling the survival of many cancer cell 







1.4 Growth arrest specific transcript 5 (GAS5) and its snoRNAs   
1.4.1 GAS5 and its role in cancer  
GAS5 is a long intergenic RNA that was initially identified by cDNA cloning of genes 
that are expressed in growth arrested cells (Schneider et al., 1988). It acts as a 
repressor of the glucocorticoid receptor by acting as a glucocorticoid response 
element (GRE) which competitively competes with the actual DNA GRE substrate 
(Kino et al., 2010). GAS5 is located on chromosome 1q25 which is associated with 
many cancers including prostate cancer (Pickard et al., 2013). The GAS5 gene 
consists of 12 exons with a very short open reading frame and many stop codons 
within its sequence. Exon 1 contains a 5'-terminal oligopyrimidine (5'-TOP) tract, a 
common motif found in genes that encode proteins and involved in the biogenesis 
of ribosomes and translation. The GAS5 transcript hosts ten snoRNAs within its 
introns and is therefore classified as a snoRNA host gene (Smith and Steitz, 1998). 
These snoRNAs are called U74, U75, U76, U77, U44, U78, U79, U80, U47 and 
U81. While U44 is involved in the 2'-O-methylation of 18S rRNA; the rest of these 
snoRNAs serve as a guide to modify 28S ribosomal RNA (Smith and Steitz, 1998). 
The location of these snoRNAs within the transcript is shown in Figure 8. 
 
 
Smith and Steitz (1998) confirmed that GAS5 transcripts are elevated in growth 
arrested cells which agrees with Schneider et al., (1988). The reason behind GAS5 
accumulation is the interplay of the mammalian target of rapamycin (mTOR) 
pathway (important in regulation of the cell cycle) and nonsense-mediated decay 
Figure 8: GAS5 is a multi-snoRNA host gene. The black boxes represent the 12 exons in the GAS5 
transcript. The hatched boxes represent the snoRNAs present in the transcript. The lines above exon 
6/7/8 represent the alternative splicing that occurs to include exon 7 (Smith and Steitz, 1998) 
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(NMD) pathway (reduces errors in gene expression by removing stop codons in 
mRNA sequences). Due to the presence of the 5'-TOP sequence, GAS5 translation 
would be promoted in actively growing cells due to the increased activity of mTOR 
pathway. However, the presence of short open reading frame and multiple stop 
codons in the GAS5 transcript lead to the degradation of the GAS5 transcripts via 
the NMD pathway resulting in a decrease in GAS5 transcript levels in the actively 
growing cells. However, the decrease in the activity of the mTOR pathway in growth 
arrested cells implies that GAS5 will not be translated, resulting in a reduced 
degradation of its transcripts by the NMD pathway and the accumulation of its 
transcripts (Pickard and Williams, 2014).  
Early studies have shown that the GAS5 transcript displays many patterns of 
alternative splicing and in fact has a very small open reading frame that is poorly 
conserved (Muller et al., 1998). The human GAS5 gene, along with hosting 
snoRNAs, has two full length isoforms and 5 expressed sequence tags (ESTs) 
formed from alternative splicing of the transcript (Figure 9). The two isoforms differ 


















Mourtada-Maarabouni et al. (2008) established that GAS5 has a crucial role in 
apoptosis and in regulating normal growth arrest in both T-leukemic cell lines and 
non-transformed human lymphocytes. Their work showed that overexpression 
of GAS5 in the T-leukemic cell lines causes both an increase in basal apoptosis and 
in cell cycle arrest in G0/G1. They also confirmed that GAS5 downregulation inhibits 
apoptosis and results in an increased rate in cell cycle progression, highlighting the 
fact that GAS5 expression is important for normal growth arrest in leukemic T-cell 
lines as well as human peripheral blood T-cells. Transfecting the different ESTs into 
leukemic T-cell lines had different effects on the cells. Transfecting GAS54A into 
leukemic cells resulted in a reduced in cell number by 77%. Transfecting GAS5O1 
also resulted in a lower cell density and viable cell density compared to the control 
with a percentage decrease of 56%. 
Figure 9: The organization of the GAS5 gene and its ncRNA products. The human GAS5 
ncRNAs are produced due to alternative splicing which includes or removes exon 7. There are 
also 5 expressed sequence tags of the human GAS5 transcript in which can be seen above all 
ranging in size. The * depicts where the siRNA was placed in the transcript to form the shorter 
transcripts seen in the two ncRNAs and GAS5O1, GAS54A and GAS54B (Kino et al., 2010).  
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Further studies examined the effects of modulation of GAS5 expression levels on 
breast and prostate cancer cell fate. Mourtada-Maarabouni et al. (2009) showed that 
overexpression of GAS5 in the human breast cancer cell line MCF-7, the non-
tumorigenic breast epithelial cell line MCF-10A and additionally the human 
embryonic kidney HEK293T cell line resulted in increased levels of basal 
apoptosis and increased sensitivity of the cells to many apoptotic stimuli. In 
addition, Mourtada-Maarabouni et al., (2009) showed a decrease in GAS5 transcript 
levels in samples from breast cancer patients compared to control samples. Pickard 
et al. (2013) also reported a decreased GAS5 expression level in cDNA samples 
from patients with prostate cancer compared to cDNA from normal tissue. The study 
also investigated whether GAS5 overexpression influences apoptosis and cell 
survival in prostate cancer cell lines.  Plasmid containing various GAS5 transcripts, 
including mature GAS5 and a cloned GAS5 sequence containing exons 1-12, were 
transfected into 22Rv1 and PC-3 prostate cancer cells. The results showed an 
increase in apoptosis drastically as the expression of GAS5 increased. The use of 
GAS5 transcript with exons 1-12 present confirms that the exons alone are enough 
to cause the apoptotic effects in prostate cancer cell lines. 
Subsequent studies have confirmed that GAS5 is involved in different types of 
cancers where it can act as tumour suppressor. The levels of GAS5 transcripts have 
been found to be lower in Renal Cell Carcinoma (RCC) patient tissues than normal 
tissue samples (Qiao et al., 2013). GAS5 was transfected into the human RCC A498 
cell line to determine whether it influences the survival of these cells. From functional 
assays on the GAS5 transfected RCC cells, it was concluded that overexpressing 
GAS5 in A498 RCC cells induces apoptosis, interrupts the cell cycle and inhibits cell 
proliferation. Sun et al. (2014) found that the levels of GAS5 transcripts are 
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downregulated in gastric cancer and a lower level of GAS5 transcripts in gastric 
cancer correlated with a poor survival rate of patients. Overexpressing GAS5 in 
gastric cancer cells resulted in a reduced cell growth rate compared to cells with 
GAS5 silenced. Performing a colony forming assay with the cells that have 
overexpression of GAS5 resulted in poor colony formation. GAS5 overexpression 
also induced apoptosis in gastric cancer cells. Interestingly, the overexpression of 
GAS5 was also performed in vivo, using nude mice. From this experiment, it was 
observed that overexpressing GAS5 in these mouse models inhibited tumour 
growth.  Wang et al. (2018) confirmed that GAS5 has pro-apoptotic effects using 
bladder cancer cells. GAS5 has a low expression in bladder cancer cell lines and its 
overexpression resulted in an increase in apoptosis. From a previous study by this 
research group, it was shown that Enhancer of zeste homolog 2 (EZH2) is essential 
for regulation of cell activity of bladder cancer cells. EZH2 participates in histone 
modification and is found on the Polycomb Repressive Complex 2 (PRC2), which is 
responsible for healthy embryonic development. This study has shown that GAS5 
negatively regulated EZH2 transcription in these cells and therefore a lower 
expression of EZH2 was observed.  
Identifying novel biomarkers is of great value to identify different stages and 
progression of diseases. Han et al., (2016) evaluated the GAS5 transcript as a 
biomarker for assessing the progress a patient is making after breast surgery. This 
research concluded that the GAS5 transcript could be used a biomarker post breast 
surgery. Liang et al., (2016) agreed with the use of the GAS5 transcript as a 
biomarker alternatively for non-small cell lung cancer. PCR was conducted to 
analyse the expression levels of the GAS5 transcript in all samples. As expected, 
the levels of the GAS5 transcript in NSCLC patients were significantly lower than in 
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healthy samples. To further enhance the reliability of this study, the levels of the 
GAS5 transcript were measured after surgery to remove the tumour. 7 days post-
surgery, the expression of the GAS5 transcript increased. Using the data collected 
it was concluded that the GAS5 transcript can be used as a biomarker to detect 
NSCLC. 
1.4.2 GAS5 snoRNAs  
As mentioned earlier, GAS5 is a host gene to ten C/D box snoRNA genes, 9 of 
which including U74, U75, U76, U44, U78, U79, U80, U47, and U81 are encoded 
within introns. The fourth intron does not produce a stable detectable RNA molecule 
but has been named as SNORD77 (Smith and Steitz, 1998). Studies have reported 
that GAS5 derived snoRNAs have an increased expression in various diseases, 
suggesting that they may play a role in the pathogenesis of this diseases.   
Krell et al., (2014) performed a paramount analysis on the expression levels of RNA 
molecules in patients with colorectal cancer compared to healthy patients and 
showed that two snoRNA molecules derived from the GAS5 transcript, SNORD47 
(U47) and SNORD44 (U44), have an increased level in patients with colorectal 
cancer. SNORD47 found between exons 10 and 11 of the GAS5 transcript, has 
been indicated to be a tumour suppressor in glioblastoma. Xu et al. (2017) 
overexpressed SNORD47 in glioblastoma cells and noted that it inhibited the 
proliferation, colony formation, migration and the invasion abilities of these cells. 
Cell cycle analysis also showed a G2-phase arrest. This suggests a tumour 
suppression capability of SNORD47 in glioblastoma. The effects of SNORD47 in 
vivo was also studied in conjunction with the chemotherapeutic drug temozolomide. 
The brain tissues of the subjects were stained to reveal that treating with SNORD47 
and temozolomide, both separately and in conjunction, reduced the tumour volume. 
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Combining both therapies improved the efficiency of the chemotherapeutic drug (Xu 
et al., 2017). In hepatocellular carcinoma (HCC), U47 has been shown to have an 
opposite effect to those reported in glioblastoma by Xu et al. (2017). SNORD47 is 
highly expressed in HCC cells compared to adjacent healthy tissue samples. This 
study also identified that patients with high levels of SNORD47 had a poor survival 
rate compared to patients with tumours with low amounts of SNORD47. Further 
functional analysis showed that a knockdown of SNORD47 in HCC cells induces 
apoptosis and suppressed cell invasion (Li et al., 2017). The conclusion from this 
study was that SNORD47 promotes tumorigenesis in HCC.  
Two GAS5 snoRNAs, U74 and U80, have also been shown to be significantly 
downregulated in NSCLC (Gao et al., 2014). Wu et al. (2018) studied the clinical 
significance of SNORD76 (U76) as an oncogene and a potential diagnostic 
biomarker in hepatocellular carcinoma. SNORD76 is found in the GAS5 transcript 
in between exons 3 and 4. SNORD76 knockdown inhibited the proliferation of 
hepatocellular carcinoma cells by inducing apoptosis and causing the cells to arrest 
at G0/G1 in the cell cycle. On the other hand, overexpressing SNORD76 caused an 
increase in cell proliferation. This study suggests that SNORD76 may have a role in 
tumorigenicity and therefore could be used as a potential biomarker as its 
expression is increased during the production of tumours. 
SNORD44 is a C/D box snoRNA found between exon 5 and 6 of the GAS5 
transcript. Krell et al. (2014) found that there was a strong correlation between p53 
expression, a tumour suppressor, and SNORD44. Levels of p53 was found to be 
increased in colorectal cancer tissues compared to normal colorectal tissues. Levels 
of p53 was then correlated with SNORD44 levels to determine whether a 
relationship existed. Using Pearson’s correlation coefficient, it was found that a 
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positive correlation exists between the levels of p53 and SNORD44. This suggests 
a possible link between p53 and SNORD44.  P53 regulates cellular response to 
DNA damage so this could mean SNORD44 may have an important role in this 
response. Such results suggest that SNORD44 may have an important function in 
tumour suppression and highlight the importance to study the function of this 
snoRNA in the control of cell fate.   
1.5 Aims of the study  
The aims of this study are to investigate the hypothesis that SNORD44 may play a 
role in the regulation of leukemic cell survival. The study will determine the effects 
of SNORD44 overexpression on leukemic T cell survival.    
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2 Materials and Methods  
2.1 Materials  
2.1.1 Cell culture 
RPMI-1640 medium (# R0883), L-Glutamine (# G7513) and Gentamicin (# G1272) 
were all purchased from Sigma-Aldrich. Fetal bovine serum (FBS) (# FB-1001S) 
was purchased from Biosera.  
2.1.2 Transient transfections 
Iscoves Modified Dulbecco’s medium (# I3390) was from Sigma-Aldrich. Ingenio 
solution (# MIR50111) and nucleofection cuvettes (# MIR50115) were purchased 
from Mirus Bio LLC. The NucleofectorTM 2b device (# AAB-1001) was from Lonza 
Biosciences. 0.4 mm electroporation cuvettes (# FBR-204) were from Scientific 
laboratory supplies Ltd. Bio-Rad Gene Pulser II (# 1652660) was purchased from 
Bio-Rad. Opti-mem® medium (# 31985062) was from Gibco. Endofree plasmid 
maxi kit (# 12362) was obtained from Qiagen (Crawley, UK). Z-VAD-FMK (# G7231) 
was purchased from Promega. 
2.1.3 Short term functional assays 
Trypan Blue (# T8154) and acridine orange (# A6014) were from Sigma-Aldrich. 
Muse Cell Analyser (# 0500-3115), Muse® Count and Viability assay kit (# 
MCH100102) and Muse Cell Cycle assay kit (# MCH100106) were purchased from 
Merck Millipore (Darmstadt, Germany). MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (# G5421) was 
purchased from Promega. 
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2.1.4 RNA isolation and Reverse transcription  
TriSureTM (# BIO-38032) was purchased from Bioline (London, UK). Direct-zol RNA 
Miniprep kit (# R2050) was purchased from Zymo Research. miRCURY LNA miRNA 
RT Kit (# 339340) was from QIAGEN. Thermo-Cycler (# WZ-93945-09) was from 
Cole-Palmer. Nanodrop 1000 spectrometer was obtained from Thermo-Fisher 
Scientific. 
2.1.5 RT-PCR 
miRCURY® LNA miRNA PCR Assay Kit (# 339345), SNORD44 (# YP00203902) 
and U6 primers (# YP00203907) were purchased from QIAGEN. AriaMx Real Time 
PCR System (# G8830A) was purchased from Agilent Technologies. 
2.2 Methods  
2.2.1 Cell culture  
Two cell lines, Jurkat and CEM-C7 cell lines, were used in the present study. Both 
Jurkat and CEM-C7 cells are T-lymphocytic leukemia cell lines. Both cell lines were 
cultured in RPMI-1640 medium with added 10% Fetal Bovine Serum (FBS), 2 mM 
L-Glutamine and 200 g/ml gentamicin. RPMI-1640 medium supplemented with the 
above is complete. The cell lines were grown in a humidified incubator at 37oC with 
5% CO2. All cells were passaged every 3-4 days to replenish the medium. To 
passage the cells, a sterile 25 ml flask was used in which 9 ml of RPMI-1640 medium 
at 37oC was added. 1 ml of cells was added to the medium in the flask and were 
then incubated at 37oC with 5% CO2. Cell stocks were replaced every two months 
with fresh stocks. All experiments were performed using cells in the log phase. 
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2.2.2 Maxi prep of SNORD44 and SNORD44 mutant 
The U44 sequences TOPO cloned into pcDNA3.1 V5-His-TOPO vector were 
obtained from Dr. Mark Pickard and Prof. Gwyn Williams (Keele University). The 
mutant U44 sequence was PCR-amplified from Jeko-1, the mantle cell lymphoma 
cell line whereas the wild type U44 was PCR-amplified from CEM-C7 cells. PCR 
amplified sequences were TOPO cloned into pcDNA3.1 V5-His-TOPO vector Life 
Technologies Ltd. (Paisley, UK). 
Glycerol stocks of pcDNA3.1-SNORD44 wild type (pcDNA3.1-U44), pcDNA3.1-
mutant SNORD44 (pcDNA3.1-U44(-)) and empty vector pcDNA3.1 in Escherichia 
coli (E. coli) were cultured for 24 hours to increase the amount of plasmid available 
in the E. coli. To culture the bacteria from the glycerol stocks, 5 ml of LB broth media 
was supplemented with 5 µl of 100 mg/ml Ampicillin in a universal tube. A pipette 
tip with a small amount of glycerol stock was added to this LB media. This was then 
incubated in a shaker for 6 hours at 37oC. After 6 hours, 100 ml LB media was added 
to a conical flask along with 100 µl Ampicillin. 1-2 ml of culture was added to this 
conical flask and was incubated overnight on a shaker at 37oC. After 24 hours, the 
culture was centrifuged at 6000xg for 15 minutes at 4oC, and all supernatant was 
removed. The QIAGEN Endofree plasmid maxi kit was used to purify the plasmid 
DNA following the kit protocol. The cells were resuspended in buffer P1 and an 
identical quantity of the lysis buffer P2 was then introduced and incubated for 10 
minutes. The neutralisation buffer P3 was added and the solution was transferred 
into the QIAfilter cartridge and a further incubation period of 10 minutes was 
completed before inserting a plunger into the cartridge to filter the cell lysate. Buffer 
ER was then added to the lysate and an incubation of ice for 30 minutes occurred. 
Buffer ER removes endotoxins from the lysate. A QIAGEN-tip 500 was then 
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equilibrated with buffer QBT (equilibration buffer). Once the incubation period is 
over, the filtered lysate was added to the QIAGEN-tip 500 to allow it to filter by the 
gravity flow. The QIAGEN-tip 500 was then washed twice with buffer QC (wash 
buffer). The first wash was to remove all contaminants. The second wash was 
necessary as a large quantity of culture was being used; this ensured that all 
contaminants were removed completely. Buffer QN (elution buffer) was then used 
to elute the DNA that was extracted. The DNA was then precipitated by adding room 
temperature isopropanol and centrifuging at 15,000 x g for 15 minutes at 4oC. The 
isopropanol also washes away all the remaining salt residues. The pellet gained 
from this centrifugation was then washed using endotoxin free room temperature 
70% ethanol and centrifuged for a further 10 minutes at 15,000 x g and 4oC. This 
step facilitates the replacement of isopropanol with ethanol as it is more volatile and 
allows the DNA to be re-dissolved easier. The collected DNA pellet was then 
resuspended in buffer TE. Buffer TE protects the DNA from degradation. To check 
the concentration of the DNA product produced, the NanoDrop 1000 
spectrophotometer was used. DNA with a 260/280 ratio of ~1.8 was considered 
good quality DNA. The identity of the plasmid DNA and insert were verified by 
sequencing (MWG, Eurofins). See Appendix A for the blast results from the 
sequences received. 
2.2.3 Nucleofection 
1x106 Jurkat cells were collected from a 25 ml flask. Cells were centrifuged and 
resuspended in 100 l Ingenio solution and added to nucleofection cuvettes along 
with 2 g DNA. The NucleofectorTM 2b device (Lonza) was used to introduce the 
DNA into the cells using the programme A-017. Cells were recovered in Iscoves 





1x107 CEM-C7 cells were collected from a 25 ml flask. Cells were centrifuged and 
resuspended in 1X Opti-mem® medium. 400 µl of 1X Opti-mem® medium was used 
for each sample. 0.4 cm gap cuvettes were used to perform the electroporation. 
plasmid DNA was added to the cuvettes along with the cells. Empty pcDNA3.1 
vector, SNORD44 and SNORD44(-) were transfected into the cells with the 
parameters 238V (actual 250V) and a capacitance 1050F using the Bio-Rad Gene 
Pulser II. Cells were recovered in Iscoves Modified Dulbecco’s medium with added 
200 mM L-Glutamine and 20% FBS.  
 
2.2.5 Determination of cell survival and apoptosis following transfection 
At 24 hours, 48 hours and 72 hours post transfection, cell counting was performed 
by staining the cells with 0.1% w/v trypan blue and counting using a 
haemocytometer. This method is called vital dye staining and is important to 
determine the number of total and viable cells in a sample. 0.1% w/v trypan blue 
was used as a stain in this method as it would not kill living cells and would only be 
taken up by dead cells. Cells that have not stained (are white) were viable whilst 
cells that have stained blue are non-viable. To calculate the number of cells per ml, 
the following equation was used: 
Average Number of Cells in Four Large Squares X Dilution Factor X 104 
Each sample was counted 3 times and an average was taken. 
 
Additionally, viable and total cell count was analysed using flow cytometry and the 
Muse Cell Analyser (Merck). The Muse® Count and Viability assay kit was used for 
this cell count. A secondary method of counting cells is important to gain a reliable 
41 
 
set of data for total and viable cell count. This assay is based on differential 
permeability of two DNA-binding dyes. The nuclear dye stains only live cells, while 
the viability dye stains dying and dead cells. Cell debris is not counted and therefore 
excluded. To perform this assay, 20 µl of cells were suspended in 380 µl of MuseTM 
Cell Count and Viability reagent (1:20 dilution). Each sample was vortexed before 




The percentage of apoptotic cells was determined at 24 hours, 48 hours and 72 
hours using acridine orange (25µg/ml) to stain the cells. 0.5ml of cells were 
centrifuged at 1500xg for 5 minutes. The supernatant was removed, leaving 20 µl 
of supernatant at the bottom. 20 µl of acridine orange was added to the cells and 
the cells were resuspended. 20 µl of the resuspension was plated onto a microscope 
slide and a cover slip applied on top. This slide was then analysed under a 
Figure 10: Representative plots following data acquisition on Muse™ Cell Analyzer. This 
image shows an expected set of results for a count and viability assay. The first graph shows the 
viability vs the cell size. The gate set on this graph eliminates all debris from the analysis. The 
second graph shows the viability vs nucleated cells. All live cells are shown on the left of the plot 
whilst dead cells are shown on the right side of the gate. 
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fluorescent microscope. The changes in nuclear morphology of apoptotic cells 
allowed for the apoptotic cells to be identified. The percentage of apoptotic cells was 
calculated using the following equation: 
(Number of Apoptotic cells/Total Number of cells) x100 = percentage of 
apoptotic cells 
Each sample was counted 3 times and an average was taken. 
 
2.2.6 Cell cycle analysis  
Cell cycle analysis was performed to determine the percentage of cells in the sample 
that are in each stage of the cell cycle. Such analysis is important to determine 
whether transfected cells are progressing through the cell cycle in the way it would 
be expected. This assay works by staining fixed cells with propidium iodide (PI) and 
quantifying the DNA content of the cells using and flow cytometry. The cells were 
fixed to allow the dye to enter the cells as living cells would pump the dye out. Cells 
in different stages of the cell cycle stain differently by PI dye which is stoichiometric 
and will bind in proportion to the amount of DNA present in the cell. Cells in the 
G0/G1 phase will have the dimmest staining with PI, whereas cells in S phase which 
are in the process of synthesizing the DNA, will fluoresce more brightly and will 
appear between the two major peaks on the graph produced and cells in G2/M 
phase which will have double their DNA content and will stain twice as brightly as 
the G0/G1 peak.  
Cell cycle analysis was performed using the Muse Cell Analyser (Merck) and the 
muse cell cycle assay kit. 1x106 cells were transferred to a microcentrifuge tube, 24 
hours post re-plating. Cells were then centrifuged at 300 x g for 5 minutes. The 
43 
 
supernatant was then removed and 1X PBS was added to wash the cells. Cells with 
added 1X PBS were then centrifuged at 300xg for 5 minutes. The supernatant was 
then removed, leaving a small quantity of supernatant left in the bottom of the tube. 
Whilst vortexing the tube, cells were fixed by adding 1 ml of ice-cold 70% ethanol 
was added to the tube. This was then left overnight at -20oC. After the overnight 
incubation period, the cells were washed with 1X PBS and centrifuged at 300xg for 
5 minutes. The supernatant was removed, and the pellet was resuspended in 200 
l of MuseTM Cell Cycle Reagent. The resuspension was then incubated for 30 
minutes in the dark before being run on the Muse Cell Analyser. An expected set of 






Figure 11: Cell cycle profile after data acquisition on the Muse Cell analyser. An image 
shows an example of an expected set of results when performing the cell cycle assay. The 
percentage of cells in each stage of the cell cycle is shown in a table along with the mean 
intensity of the cells when stained with PI. Two graphs are produced in which the cell size vs 
DNA content and count vs DNA content is plotted. A higher number of cells in the G0/G1 phase 
is expected. The cells were gated to show % cells each phase of the cell cycle. 
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2.2.7 RNA isolation 
1x106 cells were centrifuged and resuspended in TriSureTM to lyse the cells. The 
cellular RNA was isolated using the Direct-zol RNA Miniprep kit. The protocol for 
this kit was followed. It is important that all centrifugation steps in this protocol were 
run at 13,000 x g for 30 seconds at 4oC unless the protocol stated specific time 
periods. An equal volume of 100% ethanol was added to the lysed cell suspension 
and then transferred to a Zymo-SpinTM IIC column. The mixture was then centrifuged 
at the parameters stated above. A DNase I treatment is important to perform as it 
removed possible DNA contaminants.  5 µl DNase I and 75 µl DNA digestion buffer 
were added to each column to perform the DNase treatment. This was then 
incubated for 15 minutes at room temperature. The column was then treated with 
RNA Prewash Buffer and RNA Wash Buffer. Finally, the RNA was eluted using 
RNase free water and stored at -20oC. To check if RNA was isolated, a gel was run 
in which 2 bands at 18S and 28S would be seen when a successful isolation has 
been performed. The RNA was quantified using nanodrop spectrometer 1000. Good 
quality RNA had a 260/280 nm of ~2.0. 
 
2.2.8 Real time PCR using miRCURY LNA miRNA PCR System. 
To check if transfection of SNORD44 has resulted in overexpression of the snoRNA, 
RT-PCR must be performed. The miRCURY LNA PCR System (Qiagen) was used 
as it is highly specific for the detection and quantification of small RNAs including 
miRNAs. The principle of this approach combines universal reverse transcription 
with LNA PCR amplification of the small RNA. LNA or ‘locked nucleic acids’ are a 
class of RNA analogs in which the ribose ring is described to be locked in the ideal 
conformation for Watson-Crick binding. The miRCURY LNA miRNA RT Kit was 
used to carry out reverse transcription. The approach involves addition of poly(A) 
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tail to the mature miRNA/small RNA template followed by the synthesis of cDNA 
using a Poly(T) primer with a 3’ degenerate anchor and a 5’ universal tag. The cDNA 
template is then used to amplify miRNAs or other small RNAs using two small RNA 
-specific and LNA-enhanced forward and reverse primers. The LNA enhanced 
primers ensures high sensitivity with a low background. SYBR Green is used for 













Figure 12: miRCURY LNA miRNA PCR System at a glance (Qiagen, 2018). During step one, a 
poly(A) tail is added to the template and the cDNA is then produced using the poly(T) primer. The 
poly(T) primer has a 3’ degenerate anchor and a 5’ universal tag. The cDNA template is then 
amplified in step 2 using the LNA-enhanced primers. SYBR green is then used for detection. 
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cDNA synthesis was performed on the isolated RNA using the miRCURY LNA 
miRNA RT Kit. The protocol contained in this kit was followed. To begin, the RNA 
had to be diluted to 5 ng/µl with RNase free water. The reaction mix was set up in a 
microcentrifuge tube according to the protocol with a total volume of 10 µl. The 
volumes used of each reagent from the kit are shown in Table 1.  
Table 1: Volumes of each reagent used in miRCURY LNA RT kit. The total volume reaction was 
10µl. 
Reagent Volume 
5X miRCURY RT Reaction Buffer 2 µl 
RNase-free water 4.5 µl 
10X miRCURY RT enzyme mix including  
Mg2+, RT primers and dNTPs 
1 µl 
Synthetic RNA Spike in 0.5 µl 
Template RNA (5ng/µl) 2 µl 
Total Volume 10µl 
 
UniSp6 spike-in was used to determine the quality control of the RT-PCR. The 
diluted RNA was then added to the reaction mixture and put into a thermocycler 
(cole-parmer). The cycle consisted of 60 minutes at 42oC and 5 minutes at 95oC to 
inactivate the reverse transcriptase. The mixture must then be immediately cooled 
to 4oC and can be stored in a freezer at -20oC. 
Following reverse transcription, the cDNA template was used to amplify SNORD44. 
The protocol received with the kit was followed. To begin the cDNA had to be diluted 
x60. SNORD44 and U6 primers were used in this RT-PCR, to detect not only the 
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amplification of SNORD44, but also the amplification of U6. U6 was used as the 
normaliser as it has a stable gene expression across various tissues and cells (Yi 
et al., 2018). The reaction mix was set up according to the protocol as shown in 
Table 2. 
Table 2: Table showing the volumes of reagents used for the miRCURY SYBR green PCR assay. 
Components Volume 
2X miRCURY SYBR Green Master Mix 5µl 
PCR Primer Mix 1µl 
cDNA Template 3µl 
RNase-free water 1.5µl 
Total Volume 10µl 
 
The total reaction volume for each sample was 10µl which was placed in a singular 
well of a 96-well plate. cDNA synthesised from parental cells RNA were used as a 
control. The plate was then span in a centrifuge to remove all possible bubbles 
formed when pipetting. The AriaMx Real Time PCR System (Agilent Technologies) 
was used to perform the PCR which was set up using the following parameters 
shown in Table 3.  
Table 3: Table detailing the parameters in which the SYBR green PCR assay have been set up on 
the AriaMx RT-PCR system. 
Step Time Temperature (oC) 
PCR Initial heat activation 2 minutes 95 
2-Step cycle- 40 cycles  
Denaturation 10 seconds 95 
Combined annealing/extension 60 seconds 56 
48 
 
The melting curve analysis was performed at 60-95oC. Melting curve analysis is 
important as it allows for detection of contamination. If two peaks are visible on the 
melting curve for the same sample, it suggests there is a presence of contamination.  
Expression comparisons were made relative to the calibrator using the 2-ΔΔCt 
comparative method. The equation for the ΔΔCt method is below in which the 
calibrator is the control and the normaliser is U6: 
Ct (gene of interest)sample – Ct (Normaliser)sample = ΔCt Sample 
Ct (gene of interest)calibrator – Ct (Normaliser)calibrator = ΔCt Calibrator 
ΔCt Sample – ΔCt Calibrator = ΔΔCt 
To find the overall gene expression, 2-ΔΔCt is calculated from the ΔΔCt. 
2.2.9 Z-VAD-FMK treatment  
Z-VAD-FMK is a pan caspase inhibitor. To determine whether the apoptotic property 
of SNORD44 was dependent on caspases, the pan-caspase inhibitor Z-VAD-FMK 
was utilised. Jurkat cells were grown in RPMI-1640 medium supplemented 10% 
Fetal Bovine Serum (FBS), 2 mM L-Glutamine, 200 g/ml gentamicin and one flask 
with 1 mM Z-VAD-FMK for 24 hours pre-transfection. After 24 hours, the Jurkat cells 
were transfected with pcDNA3.1-U44 or empty vector using nucleofection as 
described previously in 2.2.3. Following transfection, the total and viable cells were 
measured at 24, 48 and 72 hours post transfection. An MTS assay was also 
performed at 48 and 72 hours post transfection.  
2.2.10 MTS assay 
The MTS assay analyses the metabolic activity of cells. In the presence of 
phenazine methosulfate (PMS), MTS produces a formazan product that has an 
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absorbance maximum at 490 nm. The production of formazan is measured by a 
plate reader. An MTS assay was performed on Z-VAD treated cells transfected with 
SNORD44 and pcDNA3.1. 100 µl of cells were plated onto a 96-well plate at 48 and 
72-hours post-transfection. 3 aliquots of 100 µl per sample were taken at the two 
different time points. 20 µl of MTS reagent was added to the cells and the plate was 
incubated at 37oC for 2 hours. After this time, the plate was read using a plate reader 
and the results were plotted onto graphs.  
2.2.11 Statistical analysis 
All graphs are shown as the mean of results with the standard error of this mean. N 
stands for the number of experimental repeats performed. To determine the 
presence of statistical significance, a one-way ANOVA or unpaired t-test was 
performed. The one-way ANOVA was used to compare 3 sets of data whilst the 
unpaired t-test was used to compare 2 sets. A p value of below 0.05 was statistically 





3.1 Optimisation of transfection  
Every cell type has different requirements to provide the optimum insertion of foreign 
DNA, therefore, it is important to optimise transfection conditions before starting a 
series of experiments. It is essential to obtain the highest transfection efficiency and 
the lowest loss of viability when performing transfections. The concentration of DNA 
required to achieve the highest transfection efficiency and lowest loss of viability 
when using electroporation was determined using the plasmid pmax-GFP (Lonza) 
which encodes green fluorescent protein (GFP). A transfection using different 
concentrations of pmax-GFP plasmid (Appendix C) was performed to identify the 
concentration that will give good transfection efficiency. Four different amounts of 
pmax-GFP were used in four separate experiments, 2 µg, 5 µg, 10 µg and 20 µg. 
20 µg of pmax-GFP inhibited the cells recovery, producing a transfection efficiency 
of less than 5%. It was decided that 20 µg was too high concentration to use during 
these transfections. At 48 hours post transfection, 5 µg and 10 µg showed a 
transfection efficiency of ~50% with no significant difference between the two. 5 µg 
was used in the subsequent transfections due to the transfection efficiency being 
the highest with respect to all other amounts of pmax-GFP. The transfection 
efficiency of 10 g pmax-GFP was very similar to using 5 g therefore using the 
latter amount was more beneficial to save wastage of product (Figure 13A). The 
viability of cells transfected with 5 g and 10 g pmax-GFP showed the highest 
viability of ~75% at 48 hours but showed no significant differences to each other at 
all the three-time points. 20 g of pmax-GFP showed a cell viability of below 20% 






















Figure 13: Optimisation of plasmid DNA transfection. Electroporation of Jurkat cells were 
performed using four different amounts pmax-GFP (n=4 cultures). Transfection efficiency was 
determined using fluorescent microscopy (A). Cell viability was measured by using a 
haemocytometer and trypan blue (B). (C) shows an example of the fluorescence produced when 
pmax-GFP was transfected into cells. A one-way ANOVA and tukey test was utilised to analyse 
the significance of results, comparing the transfection efficiencies against each other. *P<0.001 









3.2 Optimisation of nucleofection programme  
The NuclofectorTM 2b device provides 3 programmes for transfection into leukemic 
cells such as Jurkat cells, these are A-017, C-016 and G-010. This optimisation is 
important as it allows a programme that provides an optimum transfection 
efficiency to be identified. The percentage viability determines the potential of the 
cells to recover after nucleofection. Nucleofection of the cells using G-010 resulted 
in viability below 70% in both the control and pmax-GFP cultures. This was 
significantly lower compared to A-017 and C-016. The viability of both A-017 and 
C-016 was around 80% for the control transfection and around 70% for the pmax-
GFP transfections. There was no significant difference between these two 
programmes in viability of transfected cells (Figure 14A). The transfection 
efficiency of these cells was also recorded after 48 hours. All transfections showed 
a statistical significance with A-017 having the highest transfection efficiency of 
pmax-GFP at 76% (Figure 14B). It was determined that A-017 was the best 
programme to use to achieve the highest transfection efficiency along with having 
























Figure 14: Ability of cells to recover after nucleofection with three different programmes. 
Three programmes were used in three separate nucleofections, A-017, C-016 and G-010 (n-
=3). Pmax-GFP was transfected into Jurkat cells along with a blank control. Percentage viability 
of Jurkat cells at 48 hours (A). The transfection efficiency was measured using fluorescent 
microscopy. (B) A one-way ANOVA and tukey test was performed to analyse the significance 
of results. * P<0.001 on comparing the same transfections using different programmes (A). 
*P<0.01 on comparing GFP transfections to each other with different programmes (B). 
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3.2 Effects of SNORD44 transient expression on the survival of Jurkat T cells 
















Figure 15: The predicted secondary structure of SNORD44. The nucleotide backbone is 
shown with all 61 bases. The 18S rRNA binding site is located at the bottom ring with the 
nucleotide sequence GCUCUAAC. The red boxes depict the D boxes within the structure 





Nucleofection was used as the method of transfection to overexpress SNORD44 in 
Jurkat cells, Jurkat cells were nucleofected with either pcDNA3.1-U44 or pcDNA3.1. 
A control was also used in which no DNA was added. Transfection of pcDNA3.1-
U44 resulted in a~16-fold increase in SNORD44 expression compared to cells 
transfected with pcDNA3.1 and mock transfected cells (Figure 16). This indicates 
that overexpression of SNORD44 has occurred in Jurkat cells following the 
















Figure 16: qRT-PCR analysis to determine SNORD44 overexpression in transfected Jurkat 
cells. Jurkat T cells were transfected with either pcDNA3.1 or pcDNA3.1-U44. A control was 
also used in which cells were nucleofected with no DNA. RNA was collected which was used to 
produce cDNA. SYBR green RT-PCR experiments were run using the cDNA produced and 
analysed using the 2-ΔΔCt method to calculate the U6:U44 ratio (n=3).  An unpaired T-test was 
used to analyse the statistical significance of the results. *P<0.0001 for pcDNA3.1-U44 
transfection compared to pcDNA3.1 transfections into Jurkat cells. U44 WT = SNORD44 
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The effects of SNORD44 overexpression on the total and viable cell number were 
determined at 24, 48 and 72 hours post-transfection, using vital dye staining. The 
viable cell count of pcDNA3.1-U44 transfected cells showed a 55% decrease after 
72 hours compared to cells transfected with empty vector (Figure 17A). The total 
cell count of pcDNA3.1-U44 transfected cells showed a 70% decrease after 72 












Figure 17: Effects of SNORD44 overexpression on the number of total and viable cell number 
of Jurkat cells. Graph of the total (B) and viable (A) cell count (cells/ml) of transfected Jurkat cells 
at 24, 48 and 72 hours post transfection of N=3 experiments as determined using vital dye staining 
after 24, 48 and 72 hours. A one-way ANOVA with tukey test was performed to analyse the statistical 
significance of the results. The asterisk above the bars symbolises a statistical significance between 
pcDNA3.1-U44 and the vector transfections. *P<0.01 comparing to mock and vector transfected 




















































To confirm the validity of the cell counting performed using a haemocytometer, flow 
cytometry was utilised to further determine the effects of SNORD44 overexpression 
on the total and viable cell count. The total cell count of pcDNA3.1-U44 transfected 
cells showed a 67% decrease after 48 hours and a 40% decrease after 72 hours 
when compared to the empty vector transfected cells (Figure 18A). The viable cell 
count of pcDNA3.1-U44 transfected cells showed a 56% decrease after 48 hours 
and a 64% decrease after 72 hours compared to cells transfected with empty vector 
(Figure 18B). The viable and total cell count was much lower in pcDNA3.1-U44 




























Figure 18: Effects of SNORD44 overexpression on the number of total and viable cell 
number of Jurkat Cells. Graph of the total (A) and viable (B) cell count (cells/ml) of transfected 
Jurkat cells at 24, 48 and 72 hours post transfection of N=3 experiments. 1x106 Jurkat cells were 
used during this nucleofection. pcDNA3.1 and pcDNA3.1-U44 were transfected into Jurkat cells. 
A control was also used in which no RNA/DNA was transfected into the cells. Using flow cytometry, 
the cell count was analysed. A one-way ANOVA with tukey test was performed to analyse the 
statistical significance of the results. The asterisk above the bars symbolises a statistical 
significance between pcDNA3.1-U44 and the vector transfections. *P<0.001 comparing vector and 
pcDNA3.1-U44 transfections at equal time points. U44 WT = SNORD44 
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Further experiments were carried out to analyse the effects of SNORD44 over-
expression on the basal apoptosis levels. To analyse the number of apoptotic cells, 
acridine orange was utilised to stain the cells. The percentage of apoptotic cells to 
total cells was then calculated and plotted onto a graph. The data shows that 
SNORD44 overexpression resulted in more than a 2-fold increase in basal 
apoptosis compared to cells transfected with pcDNA3.1 and mock transfected cells 








Cell cycle analysis was performed was also performed to assess if increased 
SNORD44 levels can affect cell cycle progression. All transfections show a very 
similar percentage of cells in each of the cell cycle stages. Cells in the G0/G1 phase 
were around 60%, S phase was ~20% and G2/M phase were around 23% (Figure 
* 
* * 
Figure 19: The effect of overexpressing SNORD44 on basal apoptosis levels of Jurkat 
cells. 1x106 Jurkat cells were used during this nucleofection (n=3). pcDNA3.1 and pcDNA3.1-
U44 were transfected into Jurkat cells. A control was also used in which DNA was not included 
in the transfection. The apoptotic cells were determined using acridine orange to stain the cell 
nuclei. A one-way ANOVA with a tukey test was performed to analyse the statistical 
significance of the results. The asterisk above the bars symbolises a statistical significance 
between pcDNA3.1-U44 and the vector transfections. * P<0.0001 comparing pcDNA3.1-U44 




20). These results showed that SNORD44 overexpression did not have any effect 












Figure 20: The effect of overexpressing SNORD44 on cell cycle progression. Cell cycle 
analysis was performed on transfected cells. Flow cytometry was used along with the Muse 
cell cycle assay kit (n=3). The cells were gated to include everything G0/G1, S and G2/M 




3.3 Effects of SNORD44 transient expression on the survival of CEM-C7 T 
leukemic cells 
 
A second leukemic T cell line, CEM-C7 was utilised to determine whether the effects 
observed due to SNORD44 overexpression is unique to Jurkat T cells or expands 
along more leukemic T cell lines. To begin, both nucleofection and electroporation 
were performed to determine which method would be the most suitable for this cell 
line. On performing nucleofection, the cells did not recover and therefore it was 
determined that nucleofection would not be suitable for this set of experiments. 
Electroporation was the method chosen for CEM-C7 cells.  
Expression analysis using real time PCR showed a significant increase in the 
expression levels of SNORD44 in cells transfected with pcDNA3.1-U44 compared 
to cells transfected with pcDNA3.1. A ~10-fold increase in SNORD44 expression 
was seen in CEM-C7 cells transfected with SNORD44 compared to those 

























The number of viable and total cells were determined at 24, 48 and 72 hours post 
transfection using vital dye staining. The total cell count decreased by 46% in the 
culture of pcDNA3.1-U44 transfected cells compared to the culture transfected with 
empty pcDNA3.1 vector at 72 hours. At 48 hours, there was a decrease of 50% in 
the total cell number comparing pcDNA3.1-U44 transfections to pcDNA3.1 
transfections (Figure 22A). The viable cell count decreased by a percentage of 49% 
from pcDNA3.1-U44 wild type transfections compared to the vector transfections at 
72 hours. Comparing these two transfections at 48 hours showed a decrease of 
44% (Figure 22B). pcDNA3.1-U44 transfections had a much lower total and viable 
cell count at 48 and 72 hours post transfection than pcDNA3.1 transfections. 
Figure 21: PCR analysis to determine the presence of SNORD44 overexpression in 
transfected CEM-C7 cells. 1x107 CEM-C7 cells were used during this nucleofection. pcDNA3.1 
and pcDNA3.1-U44 were transfected into the cells. A control was also used in which no DNA 
added to the transfected CEM-C7 cells. RNA was collected from the transfected cells and used 
to produce cDNA (n=3). SYBR green qPCR experiments were run using the cDNA produced and 
analysed using the 2-ΔΔCt method to calculate the U44:U6 ratio. An unpaired T-test was used to 
analyse the statistical significance of the results. *P<0.0001 for pcDNA3.1-U44 transfection 

















Figure 22: Effects of SNORD44 overexpression on the number of total and viable cell 
number of CEM-C7 cells. Graph of the total (A) and viable (B) cell count (cells/ml). 1x107 CEM-
C7 cells were nucleofected with pcDNA3.1 and pcDNA3.1-U44. Mock transfected cells were 
also used. Cells were counted using vital dye staining at 24, 48 and 72 hours. A one-way 
ANOVA with a tukey test was performed to analyse the statistical significance of the results. 
The asterisk above the bars symbolises a statistical significance between pcDNA3.1-U44 and 
the vector transfections. * P<0.01 comparing the transfections of vector against pcDNA3.1-U44 





















































The effects of SNORD44 overexpression on the total and viable cell count (cells/ml) 
was also assessed using flow cytometry. After 72 hours, a 33% decrease in total 
cell count (cells/ml) comparing the pcDNA3.1-U44 transfections with the vector 
transfections was observed. At 48 hours, the percentage decrease was at 40% 
comparing the total cell count (cells/ml) of pcDNA3.1-U44 transfections to empty 
pcDNA3.1 transfections (Figure 23A). The viable cell count at 72 hours showed a 
47% decrease comparing the pcDNA3.1-U44 transfections to the empty pcDNA3.1 
transfections. At 48 hours, the viable cell count of pcDNA3.1-U44 transfections 




















The effects of SNORD44 overexpression on the basal apoptosis level of CEM-C7 
was determined using acridine orange staining. At all-time points analysed, the 
percentage of apoptotic cells was significantly higher in transfections with 
pcDNA3.1-U44 than transfections with empty pcDNA3.1 vector. There was more 
than a 2-fold increase in the percentage of apoptotic cells in the cells transfected 





Figure 23: Effects of SNORD44 overexpression on the number of total and viable cell 
number of CEM-C7 cells.  Graph of the total (A) and viable (B) cell count (cells/ml). 1x107 CEM-
C7 cells were transfected with pcDNA3.1 and pcDNA3.1-U44. A control was also used in which 
no RNA/DNA was inserted. Using flow cytometry, the cell count was analysed at 24, 48 and 72 
hours post transfection (n=3).  A one-way ANOVA with a tukey test was performed to analyse 
the statistical significance of the results. The asterisk above the bars symbolises a statistical 
significance between pcDNA3.1-U44 and the vector transfections. *P<0.01 comparing 


























































A cell cycle assay was also performed and similar to the results obtained with Jurkat 
T cells, the results showed that pcDNA3.1-U44 transfection did not affect the cell 
cycle profile of CEM-C7 cells. All transfected cells showed a very similar percentage 
of cells in each stage of the cell cycle. The percentage of cells in G0/G1 was ~45%, 
S phase was ~20% and G2/M phase was ~29%. This suggests there is no effect on 
cell cycle progression when pcDNA3.1-U44 is overexpressed in CEM-C7 cells 




Figure 24: Effects of SNORD44 overexpression on basal apoptosis of CEM-C7 cells. 1x107 
CEM-C7 cells were used during this electroporation. pcDNA3.1 and pcDNA3.1-U44 were 
transfected into CEM-C7 cells. The % apoptotic cells was determined using acridine orange 
after 24, 48 and 72 hours. A one-way ANOVA with a tukey test was performed to analyse the 
statistical significance of the results. The asterisk above the bars symbolises a statistical 
significance between pcDNA3.1-U44 and the vector transfections. *P<0.01 comparing 







3.4 Effects of Overexpression of mutant SNORD44 on the viability of 
leukemic T cells  
 
SNORD44 amplified from the B lymphoma cells Jeko1 and cloned into pcDNA3.1 
(by Dr. Pickard and Prof. Williams, personal communication) showed to have two 
mutations. The mutations are located at bases 16 and 25 within the sequence. This 
heterozygous mutation changes the G bases to A. Figure 26 shows the nucleotide 
sequence of the mutated SNORD44 (SNORD44(-)) including the location of the 
mutations.  
Figure 25: The effect of overexpressing SNORD44 on cell cycle progression. Flow cytometry 
was used along with the Muse cell cycle assay kit to analyse the cell cycle of transfected cells. 
The CEM-C7 cells were stained and the assay was used in flow cytometry the day after staining. 
N=3 experiments were combined to produce this graph. The cells were gated to include G0/G1, 
S and G2/M phases and to exclude dead cells. Statistical analysis was not performed on this data. 




To overexpress SNORD44(-) in Jurkat cells, nucleofection was used. Jurkat cells 
were transfected with pcDNA3.1- and SNORD44(-) whilst control cells received no 
RNA. Expression levels of SNORD44 in transfected cells were measured using 
qRT-PCR.   Results showed that transfection with the mutant snoRNA resulted in a 
12-fold increase in the endogenous levels of SNORD44 compared to pcDNA3.1 
transfected cells (Figure 27). 
 
Figure 26: Mutant U44 snoRNA isolated from Jeko1 cell line. Diagram showing the 
nucleotide sequence of snoRNA U44 mutant including the mutations (in red) located at 


















Cells were counted at 24, 48 and 72 hours post transfection to assess the effects of 
pcDNA3.1-U44(-) overexpression on the total and viable cell count of Jurkat cells. 
The statistical analysis performed on the results shows that there was no significant 
difference between the total and viable cell count (cells/ml) of pcDNA3.1-U44(-) 
transfections and vector transfections at any time point (Figure 28 A and B).  
Figure 27: PCR analysis to determine the expression levels of SNORD44 in Jurkat cells. 
Graph to show the ratio of U44:U6 (n=3). 1x106 Jurkat cells were nucleofected with pcDNA3.1 
or pcDNA3.1-U44(-). Mock cells were nucleofected with no DNA. RNA was collected from the 
transfected cells and used to produce cDNA. SYBR green RT-PCR experiments were run 
using the cDNA produced and analysed using the 2-ΔΔCt method to calculate the U44:U6 ratio. 
An unpaired T-test was used to analyse the statistical significance of the results. *P<0.0001 
for pcDNA3.1-U44(-) transfections compared to vector pcDNA3.1 transfections into Jurkat 

















Figure 28: Effects of the overexpression of SNORD44(-) on the total and viable cell 
count of Jurkat cells. Graph of the total (A) and viable (B) cell count (cells/ml) of transfected 
Jurkat cells at 24, 48 and 72 hours post transfection of N=3 experiments. 1x106 Jurkat cells 
were used during this nucleofection. pcDNA3.1 and pCDNA3.1-U44(-) were transfected into 
Jurkat cells. A control was also used in which no RNA/DNA was transfected into Jurkat cells. 
Using a haemocytometer, cells were stained with trypan blue and counted under a 
microscope at 24, 48 and 72 hours. A one-way ANOVA with a tukey test was performed to 





















































To confirm the validity of the cell counting performed using vital dye staining, flow 
cytometry was utilised to further assess the effects of overexpression of   
SNORD44(-) on the cell number.  While no effects on viable and total cell count after 
24 and 48 were observed, a 10% increase in the number of total and viable cells in 
the culture of cells transfected with pcDNA3.1-U44(-) at 72 hours than in the vector 
transfected culture (Figure 29A and B). Such effects were not observed using vital 















Figure 29: Effect of overexpressing SNORD44(-) on the viable and total cell count in Jurkat 
cells. 1x106 Jurkat cells were transfected with either pcDNA3.1 or pcDNA3.1-U44(-). Using flow 
cytometry, the cell count was analysed after 24, 48 and 72 hours. (A) Represents total cell number 
and (B) represent viable cell number. A one-way ANOVA with a tukey test was performed to 
analyse the statistical significance of the results. The asterisk above the bars symbolises a 
statistical significance between pcDNA3.1-U44(-) and the vector transfections. *P<0.001 comparing 





















































Acridine orange staining revealed that overexpression of the SNORD44(-) had no 
statistical significant effects on the basal apoptosis levels, implying that    
SNORD44(-) does not affect basal apoptosis in these cells and the SNORD44 has 











The effects of overexpressing SNORD44(-) was also assessed in CEM-C7 cells 
using electroporation. Transfection of pcDNA3.1-U44(-) results in a ~16-fold increase 






Figure 30: Effect of overexpressing SNORD44(-) on basal apoptosis in Jurkat cells. Graph 
to show the percentage of apoptotic cells of transfected Jurkat cells at 24, 48 and 72 hours post 
transfection(n=3). Apoptosis rate was assessed using acridine orange.  A one-way ANOVA with 





















Similar to the results obtained with Jurkat T cells, transfection of CEM-C7 cells with 
pcDNA3.1-U44(-) did not have any significant difference on the total and viable cell 
number in these cells when compared to the control using vital dye staining (Figure 
32 A and B) and flow cytometry (Figure 33 A and B). pcDNA3.1-U44(-) transfection 
did not affect basal apoptosis levels (Figure 34). Together, these results provide 
evidence that the mutation in SNORD44 has abolished its growth inhibitory and pro-
apoptotic effects.  
Figure 31: qRT-PCR analysis to determine SNORD44 expression levels in the transfected 
CEM-C7 cells. 1x107 CEM-C7 cells were transfected with either pcDNA3.1 or pcDNA3.1-U44(-) 
(n=3). A control was the mock transfected cells. RNA was isolated and collected from the 
transfected cells and used to synthesise cDNA. SYBR green RT-PCR experiments were run 
using the cDNA produced and analysed using the 2-ΔΔCt method to calculate the U44:U6 ratio. An 
unpaired T-test was used to analyse the statistical significance of the results. *P<0.0001 for 
pcDNA3.1-U44(-) transfections compared to pcDNA3.1 transfections into CEM-C7 cells. U44 


















Figure 32: Effect of overexpressing SNORD44(-) on total and viable cell count of CEM-C7 
cells. Graph of the total (A) and viable (B) cell count (cells/ml) of transfected CEM-C7 cells at 24, 
48 and 72 hours post transfection using vital dye staining (n=3). A one-way ANOVA with a tukey 





































































Figure 33: Effect of SNORD44(-) overexpression on total and viable cell count of CEM-C7 
cells. Graph of the total (A) and viable (B) cell count (cells/ml) of transfected CEM-C7 cells at 24, 
48 and 72 hours post transfection (n=3). CEM-C7 cells electroporated with pcDNA3.1 and 
pcDNA3.1- U44(-). Cell number was determined using flow cytometry. A one-way ANOVA and tukey 





























































Figure 34: Effect of overexpression of SNORD44(-) on basal apoptosis of transfected CEM-
C7 cells. Graph to show the percentage of apoptotic cells of transfected CEM-C7 cells at 24, 48 
and 72 hours post transfection (n=3). Apoptosis was determined using acridine orange staining. 
A one-way ANOVA and tukey test was performed to analyse the statistical significance of the 




3.5 Effects of pan-caspase Inhibitor Z-VAD-FMK on the pro-apoptotic effects 
of SNORD44  
 
In the next series of experiments, pan-caspase Inhibitor Z-VAD-FMK was used to 
determine whether the growth inhibitory and apoptotic effects caused by SNORD44 
involves caspases. Z-VAD-FMK is a pan-caspase inhibitor which binds to the 
catalytic site of caspase proteases inhibiting their activity. This binding of Z-VAD-
FMK with the proteases is irreversible. Cells were pre-incubated with the pan 
caspase inhibitor Z-VAD-FMK for 24 hours prior to transfection with pcDNA3.1-U44 
and control cells received the vehicle (10% DMSO). 24h post incubation, cells were 
transfected with either pcDNA3.1 or pcDNA3.1-U44. The results show that cells 
transfected with pcDNA3.1-U44 without pre-incubation with Z-VAD-FMK treatment 
showed a significantly lower viability at 48 hours and 72 hours compared to the 
vector as assessed using MTS assay. There was a ~23% decrease in cell viability 
in pcDNA3.1-U44 transfected cultures compared to pcDNA3.1 transfections at 48 
hours and 72 hours. Pre-incubation of Jurkat cells with Z-VAD-FMK abolished the 
growth inhibitory effects of SNORD44. The results show that SNORD44 
overexpression in Jurkat cells treated with Z-VAD-FMK did not have any effect on 
the cell viability (Figure 35). The results suggest that the pro-apoptotic activity of 





Flow cytometry was also used to confirm the results obtained with the MTS assay.  
The results showed that the total and viable cell count of cells transfected with 
pcDNA3.1-U44 and not treated with Z-VAD-FMK was significantly lower than cells 
transfected with pcDNA3.1 vector (29% and 38% respectively for total cell count and 
40% and 43% respectively for the viable cell count). On the other hand, when Jurkat 
cells were treated with Z-VAD-FMK pre-transfection, the cells transfected with 
pcDNA3.1-U44 did not show a decrease in the number of total and viable cells as 
seen in the cells without Z-VAD-FMK (Figure 36 A and B). This result was 
concordant with Figure 35 as a lower metabolic activity seen in a sample suggests 
a lower number of total or viable cells.   
Figure 35: Effect of inhibiting caspases on the apoptotic function of SNORD44 in 
transfected Jurkat cells. Jurkat cells were incubated in the absence or presence of Z-VAD-
FMK. Cells were transfected with either pcDNA3.1-U44 or empty vector. Cell viability was 
assessed using MTS at 48 and 72 hours post transfection (n=3). The bars labelled with a ‘z’ along 
the x axis signifies the samples in which Z-VAD-FMK had been applied. A one-way ANOVA with 
a tukey test was performed on the results from this experiment. The significant results are 
indicated by placing an asterisk above the bar on the graph. *P<0.01 comparing all transfections 























Figure 36: Effect of inhibiting caspases on the growth inhibitory effects of SNORD44 in 
Jurkat cells. Graph to show the total (A) and viable (B) cell count (n=3) in transfected cells that 
have been pre-incubated with Z-VAD-FMK or vehicle. Cell count was determined using flow 
cytometry at 24, 48 and 72 hours post transfection. Bars labelled with a ‘z’ along the x axis signifies 
the samples in which Z-VAD-FMK had been applied. A one-way ANOVA with a tukey test was 
performed on the results from this experiment. The significant results are indicated by placing an 
asterisk above the bar on the graph. **P<0.01 comparing all transfections to one another at equal 






















































CEM-C7 cells were also used to investigate the effects of Z-VAD-FMK pre-treatment 
on the growth inhibitory effects of SNORD44. Consistent with the observations 
obtained from Jurkat T cells, pre-incubation of CEM-C7 cells with Z-VAD-FMK 
abolished the growth inhibitory effects of SNORD44. pcDNA3.1-U44 transfection 
into CEM-C7 cells that were treated with Z-VAD-FMK and without Z-VAD-FMK for 
24 hours did not have any effects on the cell viability and the number of total and 














Figure 37: Effect of inhibiting caspases on the growth inhibitory effects of SNORD44 in 
CEM-C7 cells. Graph to show the absorbance values of transfected CEM-C7 cells which were 
treated with the presence or absence of Z-VAD-FMK (n=3). Cell viability was assessed using an 
MTS assay.  Bars labelled with a ‘z’ along the x axis signifies the samples in which Z-VAD-FMK 
had been applied. A one-way ANOVA with a tukey test was performed on the results from this 
experiment. The significant results are indicated by placing an asterisk above the bar on the 























Figure 38: Effect of inhibiting caspases on the growth inhibitory effects of SNORD44 in 
CEM-C7 cells. Graph to show the total (A) and viable (B) cell count (cells/ml) as assessed using 
flow cytometry. Bars labelled with a ‘z’ along the x axis signifies the samples in which Z-VAD-
FMK had been applied. A one-way ANOVA with a tukey test was performed on the results from 
this experiment. The significant results are indicated by placing an asterisk above the bar on the 

























































The long non-coding RNA growth arrest specific 5 (GAS5) transcript has been 
shown to have a role in regulating cell growth and apoptosis in human T-cells, 
prostate, breast cancer and colorectal cancer cells (Mourtada-Maarabouni et al., 
2009; Pickard et al., 2013; Li et al., 2018). Strong lines of evidence implicated GAS5 
in the pathogenesis of various types of cancer and supported the fact that it acts as 
tumour suppressor gene. In addition of its 12 exons, human GAS5 encodes within 
its introns ten box C/D snoRNAs U74, U75, U76, U77, U44, U78, U79, U80, U47 
and U81 (Smith and Steitz, 1998). Previous studies have confirmed that the only 
conserved regions of the GAS5 transcript between mouse and humans are the 
snoRNAs and its 5’ end sequence, suggesting that these sequences are functionally 
important and therefore they show greater conservation (Smith and Steitz, 1998). 
Recent studies have reported a link between the dysregulation of GAS5 snoRNAs 
and some types of human cancer, highlighting the need for further research to 
characterise the functions of GAS5 snoRNAs.     
The current study investigates the role of SNORD44, one of GAS5 snoRNAs, in the 
regulation of leukemic cell fate. SNORD44 is a C/D box snoRNA encoded by a 
GAS5 intron located between exon 5 and 6. The housekeeping function of 
SNORD44 is well established as it is known to serve as a guide to modify 18S rRNA. 
However, emerging evidence suggests a new role for SNORD44 in cancer. 
Decreased expression levels of SNORD44 were reported to be directly related to 
poor prognosis in breast cancer (Gee et al., 2011).  Low levels of SNORD44 was 
also described to correlate strongly with poor survival of patients with head and neck 
squamous cell carcinoma (Gee et al., 2011). On the other hand, SNORD44 is 
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upregulated in colorectal tumours compared to benign colon tissues (Krell et al., 
2014). Interestingly, SNORD44 was also upregulated in human cells infected with 
chikungunya virus, suggesting that it may be involved in the regulation of T-cell 
growth (Saxena et al., 2013). These results highlight the importance of further 
studies to characterise the function of SNORD44. The current study investigated the 
role of SNORD44 in the regulation of leukemic cell survival. The results showed that 
overexpression of SNORD44 in two different leukemic T cells Jurkat and CEM-C7 
leads to growth inhibition and an increase in basal apoptosis. Taken together, the 
results suggest that SNORD44 regulates leukemic cell survival and has pro-
apoptotic activity in these cells.    
The role of SNORD44 in the regulation of leukemic T-cell survival is unknown. The 
results from this current study have shown that SNORD44 may have an important 
role in the regulation of leukemic cell fate decision and suggests that this snoRNA 
might function independently from its host gene GAS5. Overexpressing the 
SNORD44 in two different human T-cell lines, Jurkat and CEM-C7 cells, resulted in 
an increase in the overall percentage of apoptotic cells, implying that high 
expression levels of SNORD44 induces basal apoptosis in both leukemic T cells. 
Increased SNORD44 expression levels were associated with a decrease in both 
total and viable cell number in both cell lines. The decrease in the number of total 
and viable cells is not due to the transfection process since transfection of T-cells 
with the empty vector did not affect basal apoptosis and cell number. The results 
confirm that SNORD44 regulates T cell survival and consistent with previous 
findings, it might act as a tumour suppressor gene. Other studies have reported that 
GAS5 snoRNA, SNORD76 (U76), also acts as tumour suppressor in glioblastoma 
(Chen et al, 2015). Overexpression of SNORD76 inhibited proliferation and growth 
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of glioma cells. On the other hand, decreased expression of SNORD76 was 
associated with increased survival and a more malignant phenotype (Chen et al., 
2015). Additionally, SNORD76, not its host gene GAS5, was found to be 
downregulated in glioblastoma grade IV (Chen et al., 2015), providing evidence that 
these snoRNAs might be acting independently of their host gene. GAS5 SNORD47 
(U47) was also found to act as tumour suppressor in glioblastoma. SNORD47 was 
found to be downregulated in glioma tissues samples and its levels inversely 
correlated with poor prognosis. Increased SNORD47 suppressed invasion and 
migration and sensitized the cells to the chemotherapy drug temozolomide (Xu et 
al., 2017).  However, SNORD76 was found to be upregulated in hepatocellular 
carcinoma compared to adjacent non-tumour cells and its increased expression 
level was related to a poor survival rate of patients with the disease (Wu et al., 
2018). Silencing SNORD76 in hepatocellular carcinoma cells inhibited cell 
proliferation by promoting G0/G1 cell cycle arrest and apoptosis. Knockdown of 
SNORD76 levels also resulted in decreased hepatocellular carcinoma cell growth 
in an animal model. In contrast, overexpression of SNORD76 promoted cell 
proliferation. Together, the present work and previous findings highlight the 
importance of investigating the roles of GAS5 snoRNAs to determine their potential 
as diagnostic markers and therapeutic targets.  
The growth inhibitory effects of SNORD44 in leukemic T cells are consistent with 
the effects observed with SNORD76 and SNORD46 in other cell lines. However, the 
effects of SNORD44 on cell cycle progression are not consistent with SNORD47 
and SNORD76 effects on glioma cell cycle. Chen et al., (2015) have reported that 
overexpression of SNORD76, caused a cell cycle arrest in the S phase. However, 
the data from this study showed that SNORD44 expression had no apparent effect 
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on the cell cycle. Increased SNORD44 expression levels did not affect the cell cycle 
progression and percentage of cells in each of the cell cycle phases was 
comparable to control cells. These observations together with the enhanced basal 
apoptosis levels associated with SNORD44 over-expression suggests that 
SNORD44 growth inhibitory effects are due to an increase in cell death but not to 
cell cycle arrest.  
Known guided mutations have been used in many studies to determine important 
features of a molecules structure. Liang et al. (2010), studied snR10 snoRNA, a 
yeast specific snoRNA, to determine the important functional regions of the 
structure. To do this, guide domain mutations were carried out to determine whether 
the function of this snoRNA changed.  In the present study, a mutant version of 
SNORD44 was transfected into cells to determine whether the mutation in its 
sequence can interfere with SNORD44 growth inhibitory effects. The mutations are 
located at nucleotide 16 and nucleotide 25 of the snoRNA sequence, changing G 
base to an A (Appendix A for the base sequence of SNORD44 mutant). The results 
showed that overexpression of the mutant SNORD44 did not have any effect on cell 
number or apoptosis of Jurkat and CEM-C7 cells. The proapoptotic and growth 
inhibitory effects of SNORD44 were lost in the mutant form of SNORD44.  Dong et 
al. (2008) identified a mutant form of U50 after analysing the expression levels of 
U50 in prostate cancer cells. After mutation screening, it was determined that a 
homozygous mutation of a TT deletion (2 base pairs) was found in 2 of 30 prostate 
cancer cell lines. Normal prostate cell samples did not express the mutant U50 
snoRNA. While overexpression of U50 led to inhibition of cell growth and decrease 
in short and long term cell survival of prostate cancer cells, the mutant U50 had no 
effect on these cells which suggests that the mutation has abolished the tumour 
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suppression function of U50. This study and the findings in the present study 
suggest that the mutations in U50 and SNORD44 may result in the loss of functional 
sequences and consequently the loss of their growth inhibitory and pro-apoptotic 
effects.  
The mutation at base 25 is in one of the D boxes. The mutation means that the first 
D’ Box cannot be produced which effects the rest of the structure. The second 
mutation at base 16 is located within the 19nt and 25nt reads which means these 
smaller RNA molecules cannot be produced. It can be hypothesised that the 
structure of SNORD44 is important in its apoptotic function. The predicted structure 





















In recent years, it has been well established that snoRNAs can be processed into 
miRNAs named small nucleolar RNA-derived RNAs (sdRNAs). These sdRNAs 
have been shown to have functions similar to miRNAs. A mature miRNA forms a 
RISC complex to silence target mRNA. Argonaute proteins are essential to the 
RISC complex and therefore have associations with miRNA. At least three of 
GAS5 snoRNAs may be processed to yield miRNAs. These snoRNAs include 
SNORD44 in addition to U74 and U78 (Brameier et al., 2011).  If SNORD44 is 
processed into miRNA, the miRNA product may stimulate RNA interference 
Figure 41: Predicted secondary structure of SNORD44. The locations of the 18s rRNA binding 
site and the C/D boxes are labelled in the diagram. The 19nt and 25nt sdRNA reads are shown using 
a red line from bases 2 to 26. The arrows show the location of the mutations within the structure (Bai 
et al., 2014). 
G to A G to A 
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pathways leading to inhibition of a protein or RNA involved in promoting cell survival 
and therefore leading to cell death. Ender et al. (2008) identified that snoRNA 
ACA45 is processed into smaller non-coding RNAs that associate with Ago proteins. 
It was observed that the snoRNA ACA45 product associated with Ago1 and Ago2 
similarly to miRNA. Sequencing analysis on snoRNA ACA45 showed that the 
section producing the sdRNA is conserved in mammals and therefore must have an 
important processing function. Another snoRNA derived miRNA-like non-coding 
RNA named sno-miR-28, inhibits TAF9B (a p53 stabilising gene) which controls the 
stability of p53. P53 is important to perform apoptosis and therefore sno-miR-28 
may indirectly control apoptosis induced by p53 (Yu et al., 2015). It is well known 
that miRNAs can regulate p53 which proves further that these smaller sdRNAs act 
in a similar fashion to miRNAs (Liu et al., 2017). Patterson et al. (2017) investigated 
the hypothesis that some sdRNAs may contribute to breast cancer malignancy and 
conducted RNA-seq-based comparison of the small nucleolar RNA-derived RNAs 
in MCF-7 and the metastatic MDA-MB-231 breast cancer cell lines. Results 
identified sdRNAs derived from 13 different snoRNAs, all of which are 
overexpressed in the metastatic MDA-MB-231 breast cancer cell line. sdRNA-93 
was the most prevalent of all the sdRNAs identified and inhibiting sdRNA-93 
resulted in a decrease in the ability of the breast cancer cells to invade. The 
opposite occurred when sdRNA-93 expression was increased in breast cancer 
cell lines. This suggests that sdRNA-93 plays an active role in the malignancy of 
breast cancer cell lines. Interestingly, SNORD44 produces 71.4% of all the sdRNAs 
found in the nucleolus with sdRNA lengths of 20 nt and 25 nt (Bai et al., 2014).   
piRNAs are another class of small non-coding RNA typically 26-31 nucleotides long. 
Initially these small non-coding RNAs were discovered to inhibit transposable 
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elements and maintain genomic stability. piRNAs associate themselves with PIWI 
proteins to form a complex which aid in the gene silencing of transposable elements. 
He et al. (2015) discovered that GAS5 produces a piRNA named pi-sno75 which is 
downregulated in MCF7 cells and HEK293T breast cancer cells compared to 
adjacent healthy tissue. Interestingly, this study found that pi-sno75 upregulated the 
expression of tumour necrosis factor (TNF) related apoptosis. This means that pi-
sno75 could also be a functional tumour suppressor in breast cancer cells 
originating from the GAS5 transcript. piRNAs are involved in inducing chromatin 
modifications and affects gene expression. It is interesting to investigate if 
SNORD44 can also be processed into piRNA and whether SNORD44 derived 
piRNA is involved in mediating SNORD44 effects.  
The mechanism of action as to which SNORD44 exerts its apoptotic effect is 
unknown. It has been reported that Jurkat cells do not produce p53. Cheng and 
Haas (1990) observed the presence of a heterozygous single-nucleotide 
substitution in codon 196 in Jurkat cells which results in a shorter version of p53 that 
does not hold an apoptotic effect seen normally. This factor may mean that 
SNORD44 exerts its apoptotic effect independently of p53. The Bcl-2 gene BAX is 
also mutated in Jurkat and CEM-C7 cells. These two cell lines possess two 
heterozygous frameshift mutations in codon 41 affecting Bcl-2 expression (Meijerink 
et al., 1998). BAX usually functions in the intrinsic apoptosis pathway as an 
apoptosis activator by binding to Bcl-2 to form a heterodimer. This heterodimer 
releases cytochrome C to induce apoptosis of cells. Due to this mutation being 
present in both cell lines used in the present study, it can be concluded that 
SNORD44 pro-apoptotic effects do not involve Bcl-2, BAX or P53. More analysis 
must be performed to further understand how SNORD44 causes apoptosis. 
90 
 
Caspases were first discovered in 1993, when the ced-3 gene was observed to 
encode a cysteine protease. This cysteine protease was similar to another molecule 
found earlier named human interleukin-1β-converting enzyme (Caspase-1). Miura 
et al. (1993), identified that caspase-1 was enough to induce apoptosis in Rat-1 
(rat fibroblast) cells. This study sparked many other studies to identify 11 human 
genes that encode different caspases. Caspases can be subdivided into two groups 
based on their functions. These two groups are pro-apoptotic and pro-inflammatory 
(Li and Yuan, 2008). The pro-apoptotic group of caspases can be divided again 
into two sub groups, the initiator caspases and the executioner caspases. The 
initiator caspases produce a chain reaction which activates the executioner 
caspases which perform the degradation of cellular components. An example of 
a caspase chain reaction is the intrinsic apoptotic pathway. This pathway begins 
when cytochrome c is released in response to cellular stress. Cytochrome c binds 
to apoptotic protease activating factor 1 (APAF-1) to recruit caspase-9. This leads 
to the formation of the apoptosome of caspase-9 and APAF-1 which activates the 
executioner caspases (Salvesen, 2002). To determine whether the apoptotic 
effects of SNORD44 are caspase dependent, the pan-caspase inhibitor Z-VAD-
FMK was used. Z-VAD-FMK is a synthetic permeable peptide that acts as a pan-
caspase inhibitor by binding to the catalytic site of caspases to inhibit them. This 
reaction is irreversible (Costa Pereira et al., 2018). Z-VAD-FMK has been used by 
many studies to inhibit apoptosis including Gamen et al. (1997) who used Z-VAD-
FMK to inhibit the toxicity of doxorubicin. This study also observed that Fas-
mediated apoptosis was inhibited in Jurkat cells when Z-VAD-FMK was applied to 
the cells. In the present study, when Z-VAD-FMK was applied to Jurkat and CEM-
C7 cells pre-transfection with SNORD44, the apoptotic activity and growth inhibitory 
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effects of SNORD44 were diminished. This suggests that the proapoptotic function 
of SNORD44 is caspases-dependent. More investigation is required to identify 
which caspases are involved. 
In conclusion, this study provides important evidence that SNORD44 might act as a 
tumour suppressor in leukemic T-cells by inducing apoptosis. It is not clear how 
SNORD44 is performing this function although the absence of p53 and BAX in 
Jurkat and CEM-C7 cells indicates SNORD44 mode of action does not involve these 
proteins. More studies are required to assess the diagnostic and therapeutic 
potentials of SNORD44. More research is also needed to fully understand the 
mechanisms of action of SNORD44.  
Further work is essential to further characterise SNORD44 mode of action. It would 
be beneficial to identify the proteins that SNORD44 interacts with to determine the 
way in which it exerts an apoptotic effect. To do this, a protein pulldown followed by 
mass spectrometry could be performed. Treiber et al. (2017) conducted a protein 
pulldown to identify RNA-binding proteins that bind miRNA precursors to regulate 
their expression. This protein pulldown was followed by mass spectrometry to 
identify the proteins that the miRNA hairpins interacted with. A similar approach 
could be used with SNORD44 to identify the proteins that it interacts with in leukemic 
cells. 
Determining the therapeutic potential of SNORD44 would also be very valuable 
research to conduct. To do this, oligonucleotides mimicking SNORD44 could be 
utilised. Oligonucleotide therapy is a novel method in which short strings of synthetic 
nucleotides resembles DNA. These oligonucleotides are designed to be able to alter 
the expression of targeted genes (Lundin et al., 2015). An oligonucleotide could be 
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designed to overexpress SNORD44 to allow it to exert its tumour suppressing effect. 
Pickard and Williams (2016), used a DNA oligonucleotide based on the GAS5 
hormone response element which also exerted an apoptotic effect seen from GAS5. 
This study analysed the long-term effect on breast cancer cell lines when treated 
with this oligonucleotide which resulted in a reduced colony formation. Breast cancer 
cell lines treated with the GAS5 oligonucleotide had a poor cell survival. It is also 
important to investigate the role of SNORD44 in the control of cell survival of other 
cancer cell lines and to determine its expression levels in other types of cancer. The 
role and significance of other GAS5 snoRNAs should also be investigated.  
Conclusion  
The present work determined the role of SNORD44 in the control of cell fate of 
leukemic cell lines. SNORD44 overexpression inhibited cell growth and survival in 
two leukemic cell lines. SNORD44 overexpression also enhanced basal apoptosis 
in these leukemic cells Mutations in SNORD44 led to a loss of function. Pre-
incubation with the pan-caspase inhibitor also abolished the effects produced by 
SNORD44 suggesting that the proapoptotic effects of SNORD44 are caspase 
dependent. More studies are required to determine the diagnostic and therapeutic 
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Appendix A  
Sequence results from MWG eurofins of SNORD44 mutant and 
SNORD44 wild type 
Maxi prep of SNORD44 mutant version was performed and a sample of the 
collected elution was sent to MWG eurofins to be sequenced. The correct sequence 
was received back and therefore the correct construct was produced. The first 
sequence is for SNORD44 mutant type. The highlighted section is the bases that 








The second sequence is for SNORD44 wild type, this is the correct sequence as 





Figure A-1: Sequence results from a sample of SNORD44 mutant. The highlighted section is 
the base sequence that encodes SNORD44 mutant. The red highlighted bases show the location 















Figure A-3: Results of using NCBI Blast to analyse sequencing data of SNORD44 wild 
type. Using NCBI blast showed that the sequence received back from a sample of SNORD44 
wild type isolated using maxi prep was the correct snoRNA. 
Figure A-2: Sequence results from a sample of SNORD44 wild type. The highlighted section is 




Melting curves produced when performing sybr green RT-PCR on cells 
transfected with SNORD44 mutant and wild type to determine if 
overexpression has been successful.  
A successful RT-PCR reaction would have one peak present on the melting curve. 
More than one peak suggests contamination in the samples. The first graph is from 
the transfection of SNORD44 wild type into Jurkat cells. 3 samples from the control, 
vector and SNORD44 wild type transfections were taken and run. Only one peak is 
present in these samples which suggests no contamination. 
 
The second graph is from the transfection of SNORD44 wild type into CEM-C7 cells. 
3 samples from the control, vector and SNORD44 wild type transfections were taken 
Figure B-1: Melting curve from Sybr green RT-PCR of overexpressed SNORD44 in Jurkat 
cells. 1x106 Jurkat cells were used during this nucleofection. pcDNA3.1 and snoRNA U44 wild 
type were transfected into Jurkat cells. A control was also used in which no RNA was transfected 
into Jurkat cells. RNA was collected from the transfected cells which was used to produce cDNA. 
3 separate SYBR green RT-PCR experiments were run. The melting curve shows one peak 
which suggest only one product is present and there is no contamination. 
104 
 
and run. Only one peak is present in these samples which suggests no 
contamination. 
 
The third graph is from the transfection of SNORD44 mutant into Jurkat cells. 3 
samples from the control, vector and SNORD44 wild type transfections were taken 
and run. Only one peak is present in these samples which suggests no 
contamination. 
Figure B-2: Melting curve from Sybr green RT-PCR of overexpressed SNORD44 in CEM-C7 
cells. 1x107 CEM-C7 cells were used during this nucleofection. pcDNA3.1 and snoRNA U44 wild 
type were transfected into CEM-C7 cells. A control was also used in which no RNA was 
transfected into the cells. RNA was collected from the transfected cells which was used to 
produce cDNA. 3 separate SYBR green RT-PCR experiments were run. The melting curve 




The fourth graph is from the transfection of SNORD44 mutant into CEM-C7 cells. 3 
samples from the control, vector and SNORD44 wild type transfections were taken 
and run. Only one peak is present in these samples which suggests no 
contamination. 
 
Figure B-3: Melting curve from Sybr green RT-PCR of overexpressed SNORD44 mutant in 
Jurkat cells. 1x106 Jurkat cells were used during this nucleofection. pcDNA3.1 and snoRNA U44 
mutant were transfected into Jurkat cells. A control was also used in which no RNA was 
transfected into Jurkat cells. RNA was collected from the transfected cells which was used to 
produce cDNA. 3 separate SYBR green RT-PCR experiments were run. The melting curve 




















Figure B-4: Melting curve from Sybr green RT-PCR of overexpressed SNORD44 mutant in 
CEM-C7 cells. 1x107 CEM-C7 cells were used during this nucleofection. pcDNA3.1 and snoRNA 
U44 mutant were transfected into the cells. A control was also used in which no RNA was 
transfected into cells. RNA was collected from the transfected cells which was used to produce 
cDNA. 3 separate SYBR green RT-PCR experiments were run. The melting curve shows one 












Figure C-1: Plasmid map of pmaxGFP used in transfections. The plasmid map shows the 
location of GFP using the green arrow. (Shimizu et al., 2007). 
